

UNIVERSITÀ DEGLI STUDI DI MILANO

Procedura di valutazione per la chiamata a Professore Universitario di ruolo di I fascia da ricoprire ai sensi dell'art. 24, comma 6, della Legge n. 240/2010 per il settore concorsuale 06/D2 - Endocrinologia, Nefrologia e Scienze della Alimentazione e del Benessere, (settore scientifico-disciplinare MED/14 - Nefrologia) presso il Dipartimento di SCIENZE BIOMEDICHE E CLINICHE "LUIGI SACCO", Codice concorso 4681

Maurizio Alberto Gallieni
CURRICULUM VITAE

POSIZIONE ATTUALE:

PROFESSORE ASSOCIATO DI NEFROLOGIA PRESSO LA FACOLTÀ DI MEDICINA E CHIRURGIA - UNIVERSITÀ DEGLI STUDI DI MILANO (SETTORE SCIENTIFICO DISCIPLINARE MED/14). AFFERENTE AL DIPARTIMENTO DI SCIENZE BIOMEDICHE E CLINICHE "LUIGI SACCO".

CONVENZIONATO PER LE FUNZIONI ASSISTENZIALI CLINICHE CON ASST FATEBENEFRAELLI SACCO COME DIRETTORE DI UNITÀ OPERATIVA COMPLESSA DI NEFROLOGIA E DIALISI. QUESTA POSIZIONE È RICOPERTA DAL 1° DICEMBRE 2018

INFORMAZIONI PERSONALI

COGNOME	GALLIENI
NOME	MAURIZIO ALBERTO
DATA DI NASCITA	02 GENNAIO 1960

TITOLI

TITOLO DI STUDIO

Diploma di Laura in Medicina e Chirurgia, Università degli Studi di Milano, 6 novembre 1985

TITOLO DI DOTTORE DI RICERCA O EQUIVALENTI, OVVERO, PER I SETTORI INTERESSATI, DEL DIPLOMA DI SPECIALIZZAZIONE MEDICA O EQUIVALENTE, CONSEGUITO IN ITALIA O ALL'ESTERO

Diploma di specialista in Nefrologia, Università degli Studi di Verona, 19 luglio 1989

ALTRI TITOLI CONSEGUITI

Fellow in Renal Diseases, Washington University School of Medicine, Saint Louis, MO, USA, September 1st, 1991 thru June 30, 1993

ATTIVITÀ DIDATTICA

INSEGNAMENTI E MODULI

1997-2000: Professore a Contratto per l'insegnamento di Nefrologia presso il corso di Diploma Universitario di Infermiere, Facoltà di Medicina e Chirurgia dell'Università degli Studi di Milano
1999-2007: Professore a Contratto per svolgere attività didattica tecnico-applicativa integrativa del corso di Nefrologia presso la Scuola di Specializzazione in Medicina Interna II, Facoltà di Medicina e Chirurgia dell'Università degli Studi di Milano
2008-2009: Titolare del corso di Nefrologia nel corso di Semeiotica e Sistematica I, per il corso di Laurea in Medicina e Chirurgia, Università degli Studi di Milano, Polo Universitario Centrale, linea C e

linea D, e polo Ospedale San Giuseppe, linea H (2° semestre / 3° anno),
 2008-2009: Titolare del corso di Nefrologia del terzo anno di corso della Scuola di Specializzazione in Medicina Interna, Università degli Studi di Milano.
 2008-2009: Titolare del corso “Semeiotica nefrologica” del primo anno e di “Patologia Clinica”, del terzo anno di corso della scuola di specializzazione in Nefrologia, Università degli Studi di Milano.
 2009: Titolare del corso di Nefrologia, per il corso di Medicina Specialistica per gli studenti del terzo anno del Corso di Laurea in Tecniche di Fisiopatologia Cardiocircolatoria.
 2009-2014: nessun impegno didattico in quanto in aspettativa
 2016-2017: Master in Renal Pathology. 8 ore
 Dal 2015 ad oggi:
 - Titolare del modulo di nefrologia del corso di semeiotica e patologia degli apparati - 1 (SPA-1), Laurea Magistrale Medicina e Chirurgia, polo Sacco-Vialba. 42 ore
 - Titolare del modulo di nefrologia del corso di semeiotica e patologia degli apparati - 1 (SPA-1), Laurea Magistrale Medicina e Chirurgia, polo San Giuseppe. 52 ore
 - Titolare del modulo di nefrologia, Corso System Diseases 1, International Medical School UNIMI, Pad. LITA Segrate. 16 ore (+ 25 ore attività professionalizzanti)
 - Docente scuola di specializzazione in nefrologia. 34 ore

ATTIVITÀ DI DIDATTICA INTEGRATIVA E DI SERVIZIO AGLI STUDENTI

ATTIVITÀ DI RELATORE DI ELABORATI DI LAUREA, DI TESI DI LAUREA MAGISTRALE, DI TESI DI DOTTORATO E DI TESI DI SPECIALIZZAZIONE

Attività di relatore

AA 2015/16. Università degli Studi di Milano Corso di Laurea MEDICINA E CHIRURGIA
 ZEREGA DENISE. Matr. 761614. Prevenzione del danno renale acuto da mezzo di contrasto radiologico: calcolo del rischio con uno strumento informatico. 24/03/2017

AA 2016/17. Università degli Studi di Milano Corso di Laurea MEDICINA E CHIRURGIA
 BENVENUTO MATTIA Matr. 710274. Idoneità al calcio agonistico in paziente monorene. 01/03/2018

AA 2016/17. Università degli Studi di Milano Scuola di Specializzazione in NEFROLOGIA
 CAGNA DANIELE. Matr. S59317. The effects of rituximab maintenance treatment on lupus nephritis. 10/09/2018

AA 2017/18 Università degli Studi di Milano Corso di Laurea MEDICINA E CHIRURGIA
 CASSIA MATTHIAS ARNALDO. Matr. 815116. Anti-CD20 treatment in systemic lupus erythematosus: the role of rituximab during maintenance therapy. 26/07/2018

AA 2018/19 Università degli Studi di Milano Scuola di Specializzazione in NEFROLOGIA.
 CURTO' DIEGO SERGIO DAVIDE. Matr. S61059. Dispositivo medicale VasQ: effetti clinici e condizioni emodinamiche nella fistola arterovenosa. 04/11/2020

AA 2018/19 Università degli Studi di Milano Scuola di Specializzazione in NEFROLOGIA.
 FASULO ELIANA MARIA. Matr. S61127. 1,25-diidrossivitamina D e il suo rapporto con il paratormone: nuovi predittori di progressione di malattia in pazienti con insufficienza renale cronica stadio 3. 04/11/2020

AA 2018/19 Università degli Studi di Milano Scuola di Specializzazione in NEFROLOGIA.
 IMERAJ AMANTIA. Matr. S61237. Perfusion ipotermica in reni da donatori marginali: effetti sul recupero funzionale e valore predittivo dello score istologico. 04/11/2020

AA 2018/19 Università degli Studi di Milano Scuola di Specializzazione in NEFROLOGIA.
 MONCIINO PAOLA. Matr. S61148. L'uso dell'etelcalcetide nel trattamento dell'iperparatiroidismo secondario in emodialisi. 04/11/2020

AA 2018/19 Università degli Studi di Milano Scuola di Specializzazione in NEFROLOGIA.
PERNA FRANCESCO. Matr. S61001. The impact of functional delayed graft function in the modern era of kidney transplantation. 04/11/2020

AA 2017/18 Università degli Studi di Milano Scuola di Specializzazione in NEFROLOGIA.
NIKOLLA KLODIANA. Matr. S60607. Analisi dei fattori di rischio e mortalità in 754 pazienti incidenti in emodialisi: follow-up di 20 anni. 11/03/2021

AA 2020/21. Università degli Studi di Milano Corso di Laurea MEDICINA E CHIRURGIA
PIROVANO MARTA. Matr. 873656. Funzione renale nei pazienti oncologici sottoposti a ripetute somministrazioni di mezzo di contrasto iodato: Studio retrospettivo multicentrico. 06/07/2021

AA 2020/21. Università degli Studi di Milano Corso di Laurea MEDICINA E CHIRURGIA
PEREGO ANNA. Matr. 880299. Istopatologia e clinica del danno renale acuto (AKI) in pazienti COVID-19 deceduti in terapia intensiva. 06/07/2021

Attività di correlatore.

AA 2008/09 Università degli Studi di Milano Corso di Laurea MEDICINA E CHIRURGIA
OLIVI LAURA. Matr. 660278. L'iperparatiroidismo secondario del soggetto uremico: ruolo del fibroblast-growth-factor 23. 22/07/2009

AA 2012/13 Università degli Studi di Milano Corso di Laurea MEDICINA E CHIRURGIA
BOGHEAN ION. Matr. 825858. Deficit di vitamina D nei pazienti con insufficienza renale cronica in dialisi peritoneale. 18/07/2013

AA 2018/19 Università degli Studi di Milano Corso di Laurea MEDICINA E CHIRURGIA
TEDESCO MARTINA. Matr. 842959. Ruolo del rituximab nel trattamento della glomerulosclerosi focale segmentaria idiopatica dell'adulto: risultati di uno studio multicentrico retrospettivo. 31/07/2019

AA 2018/19 Università degli Studi di Milano Corso di Laurea MEDICINA E CHIRURGIA
DAMINELLI GIULIA. Matr. 816094. Confronto della cinetica di risposta alla terapia in pazienti affetti da glomerulopatia membranosa trattati con rituximab o ciclo ponticelli: studio retrospettivo monocentrico. 15/10/2019

ATTIVITÀ DI TUTORATO DEGLI STUDENTI DI CORSI DI LAUREA E DI LAUREA MAGISTRALE E DI TUTORATO DI DOTTORANDI DI RICERCA

1992: Instructor of "Physical Diagnosis". Corso di Introduzione alla Medicina Clinica. Washington University School of Medicine, Saint Louis, MO, U.S.A.

AA 1993-1998: Tutore per l'insegnamento del corso integrato di Malattie del Rene e delle Vie Urinarie presso la Facoltà di Medicina e Chirurgia dell'Università degli Studi di Milano (Coordinatore Didattico, Prof. Guido Coggi)

AA 2001-2007: Tutore per i medici specializzandi assegnati alla U.O. Nefrologia e Dialisi Ospedale San Paolo dalla Scuola di Specializzazione in Nefrologia della Facoltà di Medicina e Chirurgia dell'Università degli Studi di Milano (Direttore, Prof. Daniele Cusi)

ATTIVITÀ DI RICERCA SCIENTIFICA

PUBBLICAZIONI SCIENTIFICHE

H index Scopus: 34; Citazioni totali: 4689

Pubblicazioni indicizzate su PubMed

1. Brancaccio D, Minetti A, Sabbioni E, Pietra R, Bugiani O, Como G, Gallieni M. Minimal laboratory investigation of uremic patients. *Kidney Int Suppl.* 1985; 17:S108-11.

2. Gilli P, Malacarne F, Storari A, Brancaccio D, Gallieni M, Andriani M, Piccoli A, Nordio M. Desferrioxamine infusion test. *Nephrol Dial Transplant*. 1987; 2(1):54-5.
3. Brancaccio D, Gallieni M, Padovese P, Anelli A, Coggi G, Uslenghi C. Dialysis amyloidosis with massive popliteal deposition of beta 2-microglobulin amyloid. *Lancet*. 1988; 2(8614):802.
4. Brancaccio D, Gallieni M, Anelli A, Padovese P. Aluminum-dependent transfusions in dialysis. *Arch Intern Med*. 1988; 148(10):2299, 2302.
5. Anelli A, Brancaccio D, Damasso R, Padovese P, Gallieni M, Garella S. Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis. Effects on acidosis, on parathyroid function, and on calcemia. *Nephron*. 1989; 52(2):125-32.
6. Brancaccio D, Gallieni M, Padovese P, Anelli A. Beta-2-microglobulin amyloidosis in uremic dialyzed patients. *Contrib Nephrol*. 1989; 70:202-7. Review.
7. Brancaccio D, Padovese P, Gallieni M, Anelli A, Lazzaroni M, Avanzini G. Overt dialysis encephalopathy and mildly raised plasma aluminium. *Lancet*. 1989; 2(8665):736.
8. Brancaccio D, Anelli A, Gallieni M, Padovese P, Coggi G, Uslenghi C. Beta-2-microglobulin amyloidosis and osteo-articular pathology of the uremic patient on regular dialysis. *Contrib Nephrol*. 1990; 77:177-86. Review.
9. Padovese P, Gallieni M, Galmozzi C, Brancaccio D. Desferrioxamine versus erythropoietin for treatment of dialysis anaemia. *Lancet*. 1990; 335(8703):1465.
10. Brancaccio D, Avanzini G, Padovese P, Gallieni M, Franceschetti S, Panzica F, Anelli A, Colantonio G, Martinelli D, Bugiani O. Desferrioxamine infusion can modify EEG tracing in haemodialysed patients. *Nephrol Dial Transplant*. 1991; 6(4):264-8.
11. Moroni GA, Cori P, Marelli F, Del Prete M, Padovese P, Gallieni M, Anelli A, Brancaccio D. Indirect evidence for transfusion role in conditioning hepatitis C virus prevalence among dialysis patients. *Nephron*. 1991; 57(3):371-2.
12. Padovese P, Gallieni M, Brancaccio D, Pietra R, Fortaner S, Sabbioni E, Minoia C, Markakis K, Berlin A. Trace elements in dialysis fluids and assessment of the exposure of patients on regular hemodialysis, hemofiltration and continuous ambulatory peritoneal dialysis. *Nephron*. 1992; 61(4):442-8.
13. Gallieni M, Brancaccio D, Padovese P, Rolla D, Bedani P, Colantonio G, Bronzieri C, Bagni B, Tarolo G. Low-dose intravenous calcitriol treatment of secondary hyperparathyroidism in hemodialysis patients. Italian Group for the Study of Intravenous Calcitriol. *Kidney Int*. 1992; 42(5):1191-8.
14. Kamimura S, Gallieni M, Kubodera N, Nishii Y, Brown AJ, Slatopolsky E, Dusso A. Differential catabolism of 22-oxacalcitriol and 1,25-dihydroxyvitamin D3 by normal human peripheral monocytes. *Endocrinology*. 1993; 133(6):2719-23.
15. Gallieni M, Brancaccio D. Which is the preferred treatment of advanced hyperparathyroidism in a renal patient? I. Medical intervention is the primary option in the treatment of advanced hyperparathyroidism in chronic renal failure. *Nephrol Dial Transplant*. 1994; 9(12):1816-9.
16. Brancaccio D, Gallieni M. Recent advances in intravenous calcitriol treatment. *Curr Opin Nephrol Hypertens*. 1994; 3(4):411-6. Review.
17. Graziani G, Como G, Badalamenti S, Finazzi S, Malesci A, Gallieni M, Brancaccio D, Ponticelli C. Effect of gastric acid secretion on intestinal phosphate and calcium absorption in normal subjects. *Nephrol Dial Transplant*. 1995; 10(8):1376-80.

18. Gallieni M, Cozzolino M. Uncomplicated central vein catheterization of high risk patients with real time ultrasound guidance. *Int J Artif Organs*. 1995; 18(3):117-21.
19. Gallieni M, Kamimura S, Ahmed A, Bravo E, Delmez J, Slatopolsky E, Dusso A. Kinetics of monocyte 1 alpha-hydroxylase in renal failure. *Am J Physiol*. 1995; 268(4 Pt 2):F746-53.
20. Kamimura S, Gallieni M, Zhong M, Beron W, Slatopolsky E, Dusso A. Microtubules mediate cellular 25-hydroxyvitamin D3 trafficking and the genomic response to 1,25-dihydroxyvitamin D3 in normal human monocytes. *J Biol Chem*. 1995; 270(38):22160-6.
21. Brancaccio D, Ghiggeri GM, Braidotti P, Garberi A, Gallieni M, Bellotti V, Zoni U, Gusmano R, Coggi G. Deposition of kappa and lambda light chains in amyloid filaments of dialysis-related amyloidosis. *J Am Soc Nephrol*. 1995; 6(4):1262-70.
22. Brancaccio D, Cozzolino M, Gallieni M. Dialysis amyloidosis: clinical aspects and therapeutic approach. *Nephrol Dial Transplant*. 1996; 11 Suppl 3:102-5. Review.
23. Brancaccio D, Gallieni M, Cozzolino M. Treatment of hyperparathyroidism--why is it crucial to control serum phosphate? *Nephrol Dial Transplant*. 1996; 11(3):420-3. Review.
24. Gallieni M, Brancaccio D, Cozzolino M, Sabbioni E. Trace elements in renal failure: are they clinically important? *Nephrol Dial Transplant*. 1996; 11(7):1232-5. Review.
25. Dusso AS, Kamimura S, Gallieni M, Zhong M, Negrea L, Shapiro S, Slatopolsky E. Gamma-Interferon-induced resistance to 1,25-(OH)₂ D3 in human monocytes and macrophages: a mechanism for the hypercalcemia of various granulomatoses. *J Clin Endocrinol Metab*. 1997; 82(7):2222-32.
26. Andreucci VE, Gallieni M, Brancaccio D. ACE-inhibitors and progression of chronic renal insufficiency: a contribution of Italian clinical research. *J Nephrol*. 1998; 11(3):105-9. Review. <http://www.sin-italy.org/jnonline/Vol11n3/105.html>
27. Gallieni M. Iron in the treatment of anemia in dialysis patients: an important support to erythropoietin. *Int J Artif Organs*. 1998; 21(11):681-6.
28. Di Leo C, Tarolo GL, Bestetti A, Tagliabue L, Del Sole A, Aliberti G, Ardemagni A, Gallieni M, Brancaccio D, Froehlich W. [Assessment of geometric, biomechanical, and osteodensitometric properties of the ultradistal radius with peripheral quantitative computerized tomography in uremic patients with severe hyperparathyroidism] *Radiol Med (Torino)*. 1999; 97(4):229-35. Italian.
29. Gallieni M, Braidotti P, Cozzolino M, Romagnoli S, Carpani P. Acute tubulo-interstitial nephritis requiring dialysis associated with intermittent rifampicin use: case report. *Int J Artif Organs*. 1999; 22(7):477-81.
30. Brancaccio D, Bellotti V, Losi B, Padovese P, Cozzolino M, Carpani P, Mangione P, Giorgetti S, Gallieni M. Effects of a vitamin E-modified dialyzer (Excebrane) on beta-2-microglobulin structure and removal. *Contrib Nephrol*. 1999; 127:147-55.
31. Gallieni M, Brancaccio D, Antonucci F, Bellinghieri G, Carpani P, Cozzolino M, D'Agostino F, Del Mastro G, Mallamace A, Memoli B. Twice versus thrice weekly administration of intravenous calcitriol in dialysis patients: a randomized prospective trial. Gruppo Italiano di Studio dell'Osteodistrofia Renale. *Clin Nephrol*. 2000; 53(3):188-93.
32. Gallieni M, Corsi C, Brancaccio D. Hyperparathyroidism and anemia in renal failure. *Am J Nephrol*. 2000; 20(2):89-96. Review.
33. Gallieni M, Cozzolino M, Brancaccio D. Transient decrease of serum bicarbonate levels with Sevelamer hydrochloride as the phosphate binder. *Kidney Int*. 2000; 57(4):1776-7.
34. Brancaccio D, Gallieni M, Niwa T, Braidotti P, Coggi G. Ultrastructural localization of advanced glycation end products and beta2-microglobulin in dialysis amyloidosis. *J Nephrol*. 2000; 13(2):129-36.

35. M. Gallieni. Central vein catheterization of dialysis patients with real time ultrasound guidance. *J Vasc Access* 2000; 1(1): 10 - 14
36. Gallieni M, Cozzolino M, Zoni U. Hemodialysis access recirculation measured with a simple and economical potassium-based dilutional method. *J Vasc Access* 2000; 1(3): 116-117.
37. Bellotti V, Gallieni M, Giorgetti S, Brancaccio D. Dynamic of beta(2)-microglobulin fibril formation and reabsorption: the role of proteolysis. *Semin Dial.* 2001; 14(2):117-22.
38. Gallieni M. Captopril-augmented renal scanning. *N Engl J Med.* 2001; 344(24):1868.
39. Canavese C, DeCostanzi E, Branciforte L, Caropreso A, Nonnato A, Pietra R, Fortaner S, Jacono F, Angelini G, Gallieni M, Fop F, Sabbioni E. Rubidium deficiency in dialysis patients. *J Nephrol.* 2001; 14(3):169-75.
40. Gallieni M, Cozzolino M, Carpani P, Zoni U, Brancaccio D. Sevelamer reduces calcium load and maintains a low calcium-phosphorus ion product in dialysis patients. *J Nephrol.* 2001; 14(3):176-83.
41. Brancaccio D, Tessitore N, Carpani P, Gammara L, Losi B, Zoni U, Maschio G, Gallieni M. Potassium-based dilutional method to measure hemodialysis access recirculation. *Int J Artif Organs.* 2001; 24(9):606-13.
42. Brancaccio D, Tetta C, Gallieni M, Panichi V. Inflammation, CRP, calcium overload and a high calcium-phosphate product: a "liaison dangereuse". *Nephrol Dial Transplant.* 2002; 17(2):201-3. Review.
43. Tetta C, Gallieni M, Panichi V, Brancaccio D. Vascular calcifications as a footprint of increased calcium load and chronic inflammation in uremic patients: a need for a neutral calcium balance during hemodialysis? *Int J Artif Organs.* 2002; 25(1):18-26. Review.
44. Gallieni M, Cucciniello E, D'Amaro E, Fatuzzo P, Gaggiotti A, Maringhini S, Rotolo U, Brancaccio D. Calcium, phosphate, and PTH levels in the hemodialysis population: a multicenter study. *J Nephrol.* 2002; 15(2):165-70.
45. Graziani G, Badalamenti S, Como G, Gallieni M, Finazzi S, Angelini C, Brancaccio D, Ponticelli C. Calcium and phosphate plasma levels in dialysis patients after dietary Ca-P overload. Role of gastric acid secretion. *Nephron.* 2002; 91(3):474-9.
46. Brancaccio D, Cozzolino M, Gorio A, Di Giulio AM, Gallieni M. Bone disease in uremic patients: advances in PTH suppression. *J Nephrol.* 2002; 15 Suppl 6:S86-93. Review.
47. Gallieni M, Conz PA, Rizzioli E, Butti A, Brancaccio D. Placement, performance and complications of the Ash Split Cath hemodialysis catheter. *Int J Artif Organs.* 2002; 25(12):1137-43.
48. Gianni ML, Bonvissuto M, Gallieni M, Testolin C, Racchi E, Riva E. Ramipril treatment in a patient with glycogen storage disease I non-A. *J Inher Metab Dis.* 2002; 25(6):515-6.
49. Di Leo C, Gallieni M, Bestetti A, Tagliabue L, Cozzolino M, Carpani P, Pozzato C, Tarolo GL, Brancaccio D. Cardiac and pulmonary calcification in a hemodialysis patient: partial regression 4 years after parathyroidectomy. *Clin Nephrol.* 2003; 59(1):59-63.
50. Brancaccio D, Cozzolino M, Galassi A, Bellasi A, Carpani P, Gallieni M. Mechanism of uremic osteodystrophy and prevention of hyperparathyroidism in the uremic patient. *G Ital Nefrol.* 2003; 20 Suppl 22:S12-6.
51. Brancaccio D, Di Leo C, Bestetti A, Carpani P, Tagliabue L, Cozzolino M, Galassi A, Luigi Tarolo G, Gallieni M. Severe cortical and trabecular osteopenia in secondary hyperparathyroidism. *Hemodial Int.* 2003;7(2):122-9.

52. Brancaccio D, Cozzolino M, Gallieni M. Hyperparathyroidism and anemia in uremic subjects: a combined therapeutic approach. *J Am Soc Nephrol* 2004;15 (Suppl 1): S21-4.
53. Fusaro M, Munaretto G, Spinello M, Gallieni M. Regression of uraemic pruritus by cyclosporin treatment in a haemodialysis patient. *Nephrol Dial Transplant*. 2004; 19(5):1338-9.
54. Cozzolino M, Gallieni M, Corsi C, Bastagli A, Brancaccio D. Management of calcium refilling post-parathyroidectomy in end-stage renal disease. *J Nephrol* 2004; 17: 3-8
55. Bellasi A, Brancaccio D, Maggioni M, Chiarelli G, Gallieni M. Salvage insertion of tunneled central venous catheters in the internal jugular vein after accidental catheter removal. *J Vasc Access*. 2004; 5(2):49-56.
56. Gallieni M. Transparent film for intravascular catheter exit-site dressings. *J Vasc Access*. 2004; 5(2):69-75.
57. Fusaro M, Munaretto G, Spinello M, Rebeschini M, Amici G, Gallieni M, Piccoli A. Soluble transferrin receptors and reticulocyte hemoglobin concentration in the assessment of iron deficiency in hemodialysis patients. *J Nephrol*. 2005; 18: 72-9.
58. Cozzolino M, Brancaccio D, Gallieni M, Galassi A, Slatopolsky E, Dusso A. Pathogenesis of parathyroid hyperplasia in renal failure. *J Nephrol*. 2005; 18: 5-8.
59. Cozzolino M, Butti A, Chiarelli G, Rocca-Rey L, Santagostino G, Gallieni M, Brancaccio D. [Cardiovascular calcification and accelerated atherosclerosis in chronic kidney disease] *Ital Heart J Suppl*. 2005; 6:25-8. Review. Italian.
60. Cozzolino M, Galassi A, Bellasi A, Butti A, Zoni U, Gallieni M, Brancaccio D. [Prevention of extraskeletal calcifications in uremia] *G Ital Nefrol*. 2005; 22 Suppl 31: S53-5. Review. Italian.
61. Cozzolino M, Brancaccio D, Gallieni M, Slatopolsky E. Pathogenesis of vascular calcification in chronic kidney disease. *Kidney Int*. 2005; 68: 429-36.
62. Neri L, Gallieni M, Cozzolino M, Rocca-Rey L, Brambilla G, Colombi A, Foa V, Brancaccio D. Work ability and health status in dialysis patients. *Int J Artif Organs*. 2005; 28: 554-6
63. Cozzolino M, Butti A, Chiarelli G, Rocca-Rey L, Bellasi A, Galassi A, Gallieni M, Brancaccio D. Nuove acquisizioni nella patogenesi dell'iperparatiroidismo secondario [New insight in the pathogenesis of secondary hyperparathyroidism] *G Ital Nefrol* 2005; 22(4):329-336
64. Ferrario VF, Sforza C, Dellavia C, Galassi A, Rocca Rey L, Chiarelli G, Cozzolino M, Gallieni M, Brancaccio D. Facial changes in adult uremic patients on chronic dialysis: possible role of hyperparathyroidism. *Int J Artif Organs*. 2005; 28:797-802.
65. Brancaccio D, Biondi ML, Gallieni M, Turri O, Galassi A, Cecchini F, Russo D, Andreucci V, Cozzolino M. Matrix GLA Protein Gene Polymorphisms: Clinical Correlates and Cardiovascular Mortality in Chronic Kidney Disease Patients. *Am J Nephrol*. 2005; 25:548-552
66. Capitanini A, Lupi A, Osteri F, Petrone I, Del Corso C, Straniti M, Gallieni M, Rossi A. Gastric pH, sevelamer hydrochloride and omeprazole. *Clin Nephrol*. 2005; 64(4):320-2.
67. Cozzolino M, Gallieni M, Galassi A, Brambilla C, Brancaccio D. Phosphate overload accelerates vascular aging in uremic patients. *Heart International* 2006; 2: 6-11. doi: 10.4081/hi.2006.6.
68. Cozzolino M, Gallieni M, Brancaccio D. Vascular calcification in uremic conditions: new insights into pathogenesis. *Semin Nephrol*. 2006; 26(1):33-7.
69. Giacomini M, Iapichino G, Armani S, Cozzolino M, Brancaccio D, Gallieni M. How to avoid and manage a pneumothorax. *J Vasc Access*. 2006; 7(1):7-14.

70. Cozzolino M, Gallieni M, Chiarelli G, Brancaccio D. Calcium and phosphate handling in peritoneal dialysis. *Contrib Nephrol.* 2006; 150:214-25.
71. Cozzolino M, Galassi A, Biondi ML, Turri O, Papagni S, Mongelli N, Civita L, Gallieni M, Brancaccio D. Serum fetuin-A levels link inflammation and cardiovascular calcification in hemodialysis patients. *Am J Nephrol.* 2006; 26(5):423-9.
72. Cozzolino M, Gallieni M, Brancaccio D, Arcidiacono T, Bianchi G, Vezzoli G. Vitamin D retains an important role in the pathogenesis and management of secondary hyperparathyroidism in chronic renal failure. *J Nephrol.* 2006; 19(5): 566-77.
73. Cozzolino M, Galassi A, Biondi ML, Butti A, Russo M, Longhini C, Gallieni M, Brancaccio D. Decreased serum fetuin-A levels after a single haemodialysis session. *Nephrol Dial Transplant.* 2007; 22(1):290-1
74. Brancaccio D, Cozzolino M, Galassi A, Chiarelli G, Butti A, Bellasi A, Rocca-Rey L, Volpi A, Anelli A, Zoni U, Fusaro M, Brambilla C, Missaglia E, Crovetto C, Russo M, Longhini C, Provenzano R, Incalcaterra F, Cerasola G, Li Vecchi M, Gallieni M. Management of secondary hyperparathyroidism in uremic patients: the role of the new vitamin D analogs. *J Nephrol.* 2007; 20(1): 3-9.
75. Arcidiacono MV, Cozzolino M, Brancaccio D, Gallieni M, Lesma E, Carelli S, Gorio A, Di Giulio AM. A role for enhanced integrin and FAK expression in uremia-induced parathyroid hyperplasia. *J Nephrol.* 2007; 20(2):228-33.
76. Davidson IJ, Gallieni M, Saxena R, Dolmatch B. A patient centered decision making dialysis access algorithm. *J Vasc Access.* 2007; 8(2): 59-68.
77. Cozzolino M, Biondi ML, Galassi A, Gallieni M, d'Eril GV, Brancaccio D. Gene polymorphisms and serum alpha-2-Heremans-Schmid levels in Italian haemodialysis patients. *Am J Nephrol.* 2007; 27(6): 639-42.
78. Gallieni M. Machiavelli and urinalysis. *Kidney Int.* 2007 Oct;72(7):896-7.
79. Cozzolino M, Galassi A, Bellasi A, Gallieni M, Brancaccio D. The bone-vasculature-axis interaction: new insights into the pathogenesis of vascular calcification. *G Ital Nefrol.* 2007 Sep-Oct;24(5):409-14.
80. Locatelli F, Zoccali C; SIR SIN Study Investigators. Clinical policies on the management of chronic kidney disease patients in Italy. *Nephrol Dial Transplant.* 2008; 23(2):621-626.
81. Gallieni M, Butti A, Guazzi M, Galassi A, Cozzolino M, Brancaccio D. Impaired brachial artery endothelial flow-mediated dilation and orthostatic stress in hemodialysis patients. *Int J Artif Organs* 2008; 31(1): 34-42.
82. Davidson IJ, Chan D, Dolmatch B, Hasan M, Nichols D, Saxena R, Shenoy S, Vazquez M, Gallieni M. Duplex ultrasound evaluation for dialysis access selection and maintenance: a practical guide. *J Vasc Access.* 2008; 9(1): 1-9.
83. Falk A, Wilson SE, Tordoir JH, Gallieni M. Complications associated with hemodialysis vascular access procedures: the case for a classification. *J Vasc Access* 2008; 9(1): 10-11.
84. Cozzolino M, Galassi A, Gallieni M, Brancaccio D. Pathogenesis and treatment of secondary hyperparathyroidism in dialysis patients: the role of paricalcitol. *Curr Vascular Pharmacol* 2008; 6: 148-153.
85. Cozzolino M, Galassi A, Pasho S, Fallabrino G, Gallieni M, Brancaccio D. Preventive measures and new pharmacological approaches of calcium and phosphate disorders. *Contrib Nephrol.* 2008;161:234-9.

86. Cozzolino M, Galassi A, Gallieni M, Brancaccio D. Successful use of low-dose intravenous paricalcitol in the treatment of severe secondary hyperparathyroidism in a haemodialysis patient. *NDT Plus* 2008; 1(3):148-150. doi: 10.1093/ndtplus/sfn018
87. Gallieni M, Cozzolino M. Calcium and phosphate: serum levels versus body balance. *Kidney Int.* 2008;74:246 (letter)
88. Gallieni M, Cozzolino M, Ronga C, Brancaccio D. Low-molecular-weight heparins should be used with caution in patients with chronic kidney disease. *Nat Clin Pract Nephrol.* 2008; 4(9):488-9.
89. Malik J, Tuka V, Kasalova Z, Chytilova E, Slavikova M, Clagett P, Davidson I, Dolmatch B, Nichols D, Gallieni M. Understanding the dialysis access steal syndrome. A review of the etiologies, diagnosis, prevention and treatment strategies. *J Vasc Access.* 2008; 9(3):155-67.
90. Gallieni M, Pittiruti M, Biffi R. Vascular Access in Oncology Patients. *CA Cancer J Clin.* 2008;58(6):323-46.
91. Chiarelli G, Beaulieu M, Cozzolino M, Singh S, Kiai M, Taylor P, Levin A, Brancaccio D, Gallieni M. Vascular access planning in peritoneal dialysis patients. *Perit Dial Int.* 2008;28(6):585-90.
92. Gallieni M, Cozzolino M, Brancaccio D, Giovannini M. Renal outcomes in the ONTARGET study. *Lancet.* 2008;372(9655):2019.
93. Cozzolino M, Gallieni M, Brancaccio D. The mechanisms of hyperphosphatemia-induced vascular calcification. *Int J Artif Organs.* 2008;31(12):1002-3.
94. Cozzolino M, Gallieni M, Brancaccio D. Inflammation and vascular calcification in chronic kidney disease: The role of Fetuin-A. *Cytokine.* 2009 Feb;45(2):70-1
95. Cozzolino M, Biondi ML, Galassi A, Turri O, Brancaccio D, Gallieni M. Matrix metalloproteinase-1 and matrix metalloproteinase-3 gene promoter polymorphisms are associated with mortality in haemodialysis patients. *Nephrol Dial Transplant* 2009;24(7):2207-12. doi: 10.1093/ndt/gfp061.
96. Cozzolino M, Pasho S, Fallabrino G, Olivi L, Gallieni M, Brancaccio D. Pathogenesis of secondary hyperparathyroidism. *Int J Artif Organs* 2009; 32(2): 75-80.
97. Gallieni M, Cozzolino M, Fallabrino G, Pasho S, Olivi L, Brancaccio D. Vitamin D: physiology and pathophysiology. *Int J Artif Organs* 2009; 32(2): 87-94
98. Brancaccio D, Gallieni M, Pasho S, Fallabrino G, Olivi L, Volpi E, Ciceri P, Missaglia E, Ronga C, Brambilla C, Butti A, Rocca-Rey L, Chiarelli G, Cozzolino M. Pathogenesis and treatment of vascular calcification in CKD. *G Ital Nefrol.* 2009; 26(S-45): 20-27.
99. Gallieni M, Saxena R, Davidson I. Dialysis access in Europe and North America: are we on the same path? *Semin Intervent Radiol* 2009; 26: 96-105.
100. Cozzolino M, Fallabrino G, Pasho S, Olivi L, Ciceri P, Volpi E, Gallieni M, Brancaccio D. Importance of vitamin D receptor activation in clinical practice. *Contrib Nephrol* 2009; 163: 213-218
101. Brancaccio D, Cozzolino M, Pasho S, Fallabrino G, Olivi L, Gallieni M. New acquisitions in therapy of secondary hyperparathyroidism in chronic kidney disease and peritoneal dialysis patients: role of vitamin D receptor activators. *Contrib Nephrol* 2009; 163: 219-226
102. Neri L, Gallieni M, Rocca Rey LA, Cozzolino M, Brancaccio D, Colombi A, Burroughs TE. Occupational stress is associated with impaired work ability and reduced quality of life in patients with chronic kidney failure. *Int J Artif Organs* 2009; 32: 291-8.
103. Cozzolino M, Gallieni M, Pasho S, Fallabrino G, Ciceri P, Volpi EM, Olivi L, Brancaccio D. Management of secondary hyperparathyroidism in the elderly patient with chronic renal disease. *Drugs Aging* 2009; 26: 457-68.

104. Brancaccio D, Bellasi A, Cozzolino M, Galassi A, Gallieni M. Arterial accelerated aging in dialysis patients: the clinical impact of vascular calcification. *Curr Vascular Pharmacol* 2009; 7: 374-80.
105. Gallieni M, Musetti C, Granata A, Olivi L, Bertoli S. Metabolic consequences of peritoneal dialysis treatment. *Panminerva Med.* 2009;51(3):175-185.
106. Gallieni M, Martini A, Mezzina N. Dialysis access: an increasingly important clinical issue. *Int J Artif Organs.* 2009;32(12):851-6.
107. Cozzolino M, Biondi ML, Galassi A, Cusi D, Brancaccio D, Gallieni M. Vascular calcification and cardiovascular outcome in dialysis patients: the role of gene polymorphisms. *Blood Purif* 2010; 29: 347-51.
108. Gallieni M, Olivi L, Mezzina N, Cozzolino M, Cusi D. [Renal effects of combined anti-hypertensive treatments] *Recenti Prog Med.* 2010;101(2):70-7. [Article in Italian]
109. Oertelt-Prigione S, Crosignani A, Gallieni M, Vassallo E, Podda M, Zuin M. Severe hepatic encephalopathy in a patient with liver cirrhosis after administration of angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker combination therapy: a case report. *J Med Case Reports* 2010;4(1):141.
110. Fusaro M, D'Angelo A, Scalzo G, Gallieni M, Giannini S, Guglielmi G. Vertebral fractures in dialysis: Endocrinological disruption of the bone-kidney axis. *J Endocrinol Invest* 2010; 33: 347-352
111. Gallieni M. High-dose oral vitamin D supplementation and risk of falls in older women. *JAMA* 2010 Aug 25;304(8):855 (letter)
112. Colivicchi F, Di Roma A, Uguccioni M, Scotti E, Ammirati F, Arcas M, Avallone A, Bonaccorso O, Germanò G, Letizia C, Manfellotto D, Minardi G, Pristipino C, D'Amore F, Di Veroli C, Fierro A, Pastorello R, Tozzi Q, Tubaro M, Santini M, Angelico F, Azzolini P, Bellasi A, Brocco P, Calò L, Cerquetani E, De Biase L, Di Napoli M, Galati A, Gallieni M, Jesi AP, Lombardo A, Loricchio V, Menghini F, Mezzanotte R, Minutolos R, Mocini D, Patti G, Patrizi R, Pajes G, Pulignano G, Ricci RP, Ricci R, Sardella G, Strano S, Terracina D, Testa M, Tomai F, Volpes R, Volterrani M; Società Scientifiche di Medicina Cardiovascolare e Medicina Interna della Regione Lazio. Prevenzione cardiovascolare secondaria dopo sindrome coronarica acuta nella pratica clinica. Documento di Consenso delle Società Scientifiche di Medicina Cardiovascolare e Medicina Interna della Regione Lazio. [Secondary cardiovascular prevention after acute coronary syndrome in clinical practice]. *G Ital Cardiol (Rome).* 2010 May;11(5 Suppl 4):35-29S.
113. Mandolfo S, Gallieni M. Uso degli anticoagulanti orali per la prevenzione della trombosi dei cateteri venosi centrali per emodialisi (Use of oral anticoagulants to prevent central venous catheter-related thrombosis in hemodialysis). *G Ital Nefrol* 2010; 27 (5): 490-497
114. Tazza L, Mandolfo S, Carbonari L, Forneris G, Di Dio M, Palumbo R, Gallieni M, Bonforte G, Carnabuci A, Cavatorta F, Aloisi M, Galli F. [Vascular access for hemodialysis: recommendations of the Vascular Access Study Group of the Italian Society of Nephrology] *G Ital Nefrol.* 2010;27(5):508-11
115. Tazza L, Galli F, Mandolfo S, Forneris G, Di Dio M, Palumbo R, Gallieni M, Bonforte G, Carnabuci A, Cavatorta F, Aloisi M, Carbonari L; PP1SIN Study Investigators. [Indications for vascular grafts as dialysis access; consensus from the Italian experience] *G Ital Nefrol.* 2010;27(5):512-21.
116. Gallieni M, Martini A, Granata A, Fusaro M. Plasma Anti-Xa Monitoring for Low-Molecular-Weight Heparins in Patients with Chronic Kidney Disease. *Clin Pharmacokin* 2010; 49(11): 773-4. (letter)
117. Cozzolino M, Biondi ML, Banfi E, Riser BL, Mehmeti F, Cusi D, Gallieni M. Ccn2 (CTGF) gene polymorphism is a novel prognostic risk factor for cardio-vascular outcomes in haemodialysis patients. *Blood Purif* 2010; 30 (4): 272-276. doi: 10.1159/000320706.

118. Davidson IJA, Yoo MC, Biasucci DG, Browne P, Dees C, Dolmatch B, Gallieni M, La Greca A, Korndorffer JR, Nolen B, O'Rear S, Peden E, Pittiruti M, Reed G, Scott D, Slakey D. Simulation training for vascular access interventions. *J Vasc Access* 2010; 11 (3): 181-190
119. Granata A, Andrulli S, Basile A, Fiorini F, Logias F, Figuera M, Gallieni M, Fiore C. Diagnosis of acute pyelonephritis by contrast enhanced ultrasonography in kidney transplant patients. *Nephrol Dial Transplant* 2011; 26(2): 715-20.
120. Fusaro M, Crepaldi G, Maggi S, Galli E, D'Angelo E, Calò L, Giannini S, Miozzo D, Gallieni M. Vitamin K, bone fractures, and vascular calcifications in chronic kidney disease: an important but poorly studied relationship. *J Endocrinol Invest* 2011; 34(4): 317-23. doi: 10.3275/7353.
121. Gallieni M, Martini A, Fusaro M. Warfarin and heterotopic ossification: good, bad or ugly? *Spinal Cord* 2011; 49(3): 483 (letter).
122. Genovesi S, Antolini L, Gallieni M, Aiello A, Brahmochary Mandal SK, Doneda A, Giussani M, Stella A, Tucci B, Valsecchi MG. High prevalence of hypertension in normal and underweight Indian children. *J Hypertension* 2011; 29 (2): 217-21
123. Gallieni M, Chiarelli G, Olivi L, Cozzolino M, Cusi D. Unsuccessful application of taurolidine in the treatment of fungal peritonitis in peritoneal dialysis. *Clin Nephrol* 2011; 75 (1): 70-3.
124. Cozzolino M, Missaglia E, Ortiz A, Bellasi A, Adragao T, Apostolou T, Vescovo G, Gallieni M. Vascular calcification in chronic kidney disease [La calcificazione vascolare nel paziente con insufficienza renale cronica]. *Recenti Prog Med.* 2010;101(11):442-452. [Article in Italian]
125. Tazza L, Mandolfo S, Carbonari L, Forneris G, Di Dio M, Palumbo R, Gallieni M, Bonforte G, Carnabuci A, Cavatorta F, Aloisi M, Galli F. Developing recommendations for vascular access for hemodialysis: Vascular Access Working Group of the Italian Society of Nephrology. *J Vasc Access* 2011; 12: 13-6.
126. Davidson IJ, Yoo MC, Biasucci DG, Browne P, Dees C, Dolmatch B, Gallieni M, La Greca A, Korndorffer JR, Nolen B, O'Rear S, Peden E, Pittiruti M, Reed G, Scott D, Slakey D. Simulation training for vascular access interventions. *J Vasc Access* 2010 Jul-Sep;11(3):181-90.
127. Granata A, Basile A, Bruno GA, Saita A, Falsaperla M, Figuera M, Gallieni M, Floccari F. A Complex Renal Cyst: It Is Time to Call the Oncologist? *Int J Nephrol* 2011; Article ID 893985, 3 pages. doi:10.4061/2011/893985
128. Gallieni M, Martina V, Rizzo A, Gravellone L, Giordano A, Cusi D, Genovese U. Central venous catheters: legal issues. *J Vasc Access* 2011;12(4):273-9.
129. Fusaro M, Crepaldi G, Maggi S, D'Angelo A, Calò L, Miozzo D, Fornasieri A, Gallieni M. Bleeding, vertebral fractures and vascular calcifications in patients treated with warfarin: hope for lower risks with alternative therapies. *Curr Vasc Pharmacol.* 2011;9(6):763-9.
130. Gravellone L, Rizzo MA, Martina V, Mezzina N, Regalia A, Gallieni M. Vitamin D receptor activators and clinical outcomes in chronic kidney disease. *Int J Nephrol.* 2011; 2011: 419524. Epub 2011 May 15.
131. Fusaro M, D'Angelo A, Naso A, Frigo AC, Miozzo D, Gallieni M, Calò LA. Treatment with calcimimetic (Cinacalcet) alters epoetin dosage requirements in dialysis patients: preliminary report. *Ren Fail.* 2011; 33(7): 732-5.
132. Neri L, Martini A, Andreucci VE, Gallieni M, Rocca Rey LA, Brancaccio D. Regimen complexity and prescription adherence in dialysis patients. *Am J Nephrol.* 2011; 34(1): 71-6.

133. Fusaro M, Crepaldi G, Miozzo D, Gravellone L, Gallieni M. Effects of vitamin K intake on gamma-carboxylated proteins, bone fractures, and vascular calcifications. *Osteoporos Int.* 2012 May;23(5):1637-8
134. Granata A, Floccari F, Ferrantelli A, Rotolo U, Di Lullo L, Fiorini F, Logias F, Gallieni M, Fiore CE. Does systematic preliminary colour-doppler study reduce kidney biopsy complication incidence? *Int J Nephrol* 2011; 2011:419093. Epub 2011 Jul 25.
135. Jongbloed F, Galassi A, Cozzolino M, Zietse R, Chiarelli G, Cusi D, Brancaccio D, Gallieni M. Clinical significance of FGF-23 measurement in dialysis patients. *Clin Nephrol* 2011; 76(3):201-209.
136. Granata A, Floccari F, Mignani R, Gallieni M. Glomerular membranous nephropathy and Werner syndrome: a case report. *Journal Am Geriatrics Society* 2011; 59(9): 1749-50. (3,66 di IF).
137. Rizzo MA, Frediani F, Granata A, Ravasi B, Cusi D, Gallieni M. Neurological complications of hemodialysis: state of the art. *J Nephrol.* 2012;25(2):170-82.
138. Bazzi C, Rizza V, Casellato D, Stivali G, Rachele G, Napodano P, Olivieri G, Gallieni M, D'Amico G. Validation of some pathophysiological mechanisms of the CKD progression theory and outcome prediction in IgA nephropathy. *J Nephrol.* 2012 Sep;25(5):810-8. doi: 10.5301/jn.5000069.
139. Granata A, Floccari F, Gallieni M. Levothyroxine and sevelamer: listen to the patient. *Endocr Pract.* 2011 Nov-Dec;17(6):961-2. (letter)
140. Tazza L, Galli F, Mandolfo S, Forneris G, Di Dio M, Palumbo R, Gallieni M, Bonforte G, Carnabuci A, Cavatorta F, Aloisi M, Carbonari L; Study Investigators PP1 SIN. Indications for vascular grafts as hemodialysis access: consensus from experience in Italy. *J Vasc Access.* 2012 Jul;13(3):279-85. doi: 10.5301/jva.5000056.
141. Cozzolino M, Stucchi A, Rizzo MA, Soldati L, Cusi D, Ciceri P, Brenna I, Elli F, Gallieni M. Vitamin D receptor activation and prevention of arterial ageing. *Nutr Metab Cardiovasc Dis.* 2012 Jul;22(7):547-52.
142. Cozzolino M, Stucchi A, Rizzo MA, Brenna I, Elli F, Ciceri P, Bover J, Cusi D, Gallieni M. Phosphate Control In Peritoneal Dialysis. *Contrib Nephrol.* 2012;178:116-23.
143. Lentini P, Granata A, Ciancio A, Gallieni M. Regular ultrasound examination of transplanted kidneys allows early diagnosis of renal cell carcinoma and conservative nephron sparing surgery. *Arch Ital Urol Androl.* 2011 Dec;83(4):195-9.
144. Fusaro M, Noale M, Viola V, Galli F, Tripepi G, Vajente N, Plebani M, Zaninotto M, Guglielmi G, Miotto D, Dalle Carbonare L, D'Angelo A, Naso A, Grimaldi C, Miozzo D, Giannini S, Gallieni M, for the Vitamin K Italian (VIKI) Dialysis Study Investigators. Vitamin K, vertebral fractures, vascular calcifications and mortality: Vitamin K Italian (VIKI) dialysis study. *J Bone Mineral Res* 2012; 27(11): 2271-2278.
145. Gallieni M, Caputo F, Filippini A, Gabella P, Giannattasio M, Stingone A, Farina M, for the ROCK-PD study investigators. Prevalence and progression of cardiovascular calcifications in peritoneal dialysis patients: a prospective study. *Bone* 2012; 51: 332-337.
146. Fusaro M, D'Angelo A, Gallieni M. Consequences of Vitamin K2 deficiency in hemodialysis patients. *Am J Kidney Dis* 2012 Jul;60(1):169 (letter to the Editor)
147. Hörl WH, Locatelli F, Haag-Weber M, Ode M, Roth K; Epo-PASS study group. Collaborators: Hörl W, Lhotta K, Loipl J, Huspek M, Gstötenbauer K, Karagyozyova R, Monova D, Shikov P, Yovchev T, Bazeva P, Nenchev N, Charasse C, Haag-Weber M, Bockreiss N, Buhl M, Dellanna F, Dragoun GP, Goller M, Klingbeil A, Knee J, Krallinger R, Menzer T, Perschon G, Toussaint K, Wichelhaus T, Kreuzer K, Brückner D, Leistikow F, Marsen T, Sacherer K, Zimmermann U, Kohnle M, Riedasch M, Brehm K, Vogt J, Morgenroth A, Herrnberger S, Zeh M, Dammerboer C, Hofmann T, Kraemer-Guth A, Wilpert J, Pröschold F, Krämer B, Lang R, Zanker B, Lubrich-Birkner I, Hemstege M, Jäkel D, Perino S, Riedl B,

Assenmacher A, Locatelli F, Albertazzi A, Colussi G, Garibotto G, Villa G, Gesualdo L, Triolo G, Cusi D, Gallieni M, Quarello F, Malberti F, Stefoni S, Tarchini R, Di Iorio BR, Di Luca M, Bordoni E, Brunori G, Della Grotta F, Fracasso A, Guerrini E, Ragaiolo M, Costanzo R, Teatini U, Dimitrov S, Sikole A, Zabzun M, Janakiewska P, Petrovska T, Rzanikoski T, Alceva M, Panova B, Daniewska D, Klatko W, Stryjewski D, Książek A, Kopecka-Mechlińska L, Kędzierski P, Nowicki M, Szurkowski M, Papliński M, Trafny R, Kuczera M, Sokalski A, Rydzewski A, Liberek T, Uzar J, Bako GC, Ionescu D, Voiculescu M, Ardelean LC, Pitea IV, Demina L, Borsukov A, Marasaev V, Fedosseev A, Dudar I, Kolesnyk M, Kostynenko T, Kuchma I, Kuriata O, Lesovoy V, Martynyuk L, Nikonenko O. Prospective multicenter study of HX575 (biosimilar epoetin- α) in patients with chronic kidney disease applying a target hemoglobin of 10-12 g/dl. *Clin Nephrol*. 2012 Jul;78(1):24-32.

148. Marinangeli G, Cabiddu G, Neri L, Viglino G, Russo R, Teatini U; Italian Society of Nephrology Peritoneal Dialysis Study Group. Collaborators: Alberghini E, Amici G, Amoroso F, Ancarani P, Ariaudo C, Aterini S, Autuly V, Ballocci S, Barattini M, Barone MT, Barone V, Bellizzi V, Bergia R, Berlingo' G, Bermond F, Bertoli M, Bertoncini L, Bertuzzi V, Biagioli M, Boccadoro R, Boier F, Bonaduce M, Bonesso C, Bonello F, Bonfante L, Bonghi AM, Bonvegna F, Boschetti MA, Bosco M, Botti P, Brandi S, Brigante M, Bruni F, Budetta F, Cadoni MC, Campus G, Cappelletti F, Caputo F, Caria S, Carlini A, Caselli AM, Caselli GM, Casuscelli Di Tocco T, Catania B, Cataldi G, Cavaliere G, Cervini P, Cesano G, Cherubini C, Chimienti D, Ciabattini F, Ciabattini M, Cioni A, Ciurlino D, Colombo P, Conte F, Conte M, Corradi B, Costa S, Cuzzocrea G, D'Adamo G, D'Aloia G, Dal Col A, Damiani FP, David P, Del Corso C, Dell'Aquila RF, Della Gatta C, De Lucia ED, De Martino A, De Padova F, De Prisco O, Del Negro N, Delli Carri P, Di Piazza N, Di Somma A, Distratis C, Donello L, Enia G, Estivi R, Fabozzi GM, Falvo E, Fanelli V, Farina V, Fasciolo F, Fatuzzo P, Fattori L, Feriani M, Ferrando C, Ferazzoli F, Ferretti A, Figliola C, Finato V, Fregonese C, Gaggi R, Galli E, Galli S, Gallieni MA, Garofalo D, Gattullo V, Gazo A, Ghiringhelli P, Giancaspro V, Gianoglio B, Gianoli P, Giovannetti E, Giudicissi A, Grandinetti F, Guarda L, Iadarola GM, La Milia V, La Rosa R, Lanzetta R, Laudon A, Licciardello DG, Lindner G, Lisi E, Lubatti C, Lucchi L, Maccarone M, Maffei C, Magarini C, Malacarne F, Mangano S, Marcon R, Marini A, Martino FK, Massanti L, Matalone M, Mauro MM, Mauro T, Mazzotta A, Memoli B, Mencherini A, Mennella G, Merico G, Micheli A, Minari M, Miranda N, Mollica A, Montagna G, Mostacci S, Mulas D, Nacca R, Oliva S, Orazi E, Paglialunga A, Palmarini D, Pappani A, Passaghe GM, Paternoster G, Perez G, Piva M, Porri MT, Presta P, Priasca G, Puricelli F, Quattrocchi G, Raimondi C, Randone S, Ricciardi D, Ricciatti AM, Rizzuto A, Rocca AR, Rondanini V, Rosa M, Rossi D, Rucci A, Rugiu C, Russo F, Russo FS, Russo GE, Saffioti S, Sama' F, Santarelli S, Santoboni A, Saraniti A, Scalamogna A, Scalzo BI, Scanziani R, Schillaci O, Schinella D, Sepe V, Sisca S, Sorino P, Sozzo E, Staffolani E, Stanziale R, Stefoni A, Stellato D, Stingone A, Strippoli P, Sturniolo A, Tancredi M, Tessarin C, Tiraboschi G, Tirotta A, Todaro I, Tommasi A, Torpia R, Torre A, Torti G, Toscani L, Traverso GB, Turri C, Ungaro N, Vecchi R, Venanzi S, Vezzoli G, Vianello S, Vinciguerra S, Virga G, Viscione M, Vitelleschi LA, Vizzardi V, Zambianchi L, Zani MB, Zuccalà A. Old and new perspectives on peritoneal dialysis in Italy emerging from the Peritoneal Dialysis Study Group Census. *Perit Dial Int*. 2012 Sep-Oct;32(5):558-65.

149. Battaglia Y, Russo L, Spadola R, Russo D; Local Coordinators. Collaborators: Apperti V, Auricchio MR, Barbato A, Bedani PL, Bellinghieri G, Costantino G, Boggi R, Bonomini M, Calabria L, Calabria M, Grimaldi M, Capuano M, Terribile M, Caputo C, Castellino S, Centrone E, Ciccarelli M, Cicchetti T, Costantino E, D'Amaro E, Dagostino F, Napolitano F, Bonifati C, Dal Canton A, Esposito P, Delgado G, D'Apice L, Di Luca M, Farfaglia P, Cantù P, Farina M, Fasianos E, Feriozzi S, Galeotti P, Fiorini F, Frattolillo P, Garibotto G, Giannattasio M, Detomaso F, Latino A, Li Vecchi M, Maffucci G, Anelli AM, Mangano S, Meneghel G, Morrone L, Mura C, Novizio D, Paglia S, Cardone F, Parsi R, Pizzini M, Polito P, Prati E, Brognoli M, Rubino F, Turchetta L, Parravano M, Sambati M, Sicignano M, Delgado G, Tarchini R, Teatini U, Gallieni M, Colussi G, Limido A, Pozzi C, Spotti D, Brancaccio D, Traversari L, Venditti G, Apperti V, Aucella F, Garganico R, Giovanni Rotondo S, Auricchio MR, Bellinghieri G, Costantino G, Boggi R, Cenerelli S, Bozzi M, Petrarulo F, Casu MD, Cavatorta F, Montesano C, Centrone E, Ferrara DD, Mazzola MA, D'Apice L, Delgado G, Dagostino F, Napolitano F, Bonifati C, D'Amaro E, De Simone W, Del Rosso G, Di Luca M, Sozzo EE, Mangione D, Emiliani G, Farina M, Fasianos R, Feriozzi S, Galeotti P, Ganadu M, Garibotto G, Giannattasio M, Detomaso F, Lusenti T, Mangano S, Manno C, Orbelli G, Parsi R, Petrarulo F, Bozzi M, Rondanini V, Russo D, Russo D, Battaglia Y, Sarli P, Sozzo E, Napoli M, Valentini WD, Viganò L. Awareness of kidney diseases in general population and in high school students. Italian report for World Kidney Days 2010-2011. *J Nephrol* 2012; 25(5):843-6.

150. Davidson IJA, Lok C, Dolmatch B, Gallieni M, Nolen B, Pittiruti M, Ross J, Slakey D. Virtual reality: Emerging role of simulation training in vascular access. *Semin Nephrol* 2012; 32:572-581.

151. Cozzolino M, Rizzo MA, Stucchi A, Cusi D, Gallieni M. Sevelamer for hyperphosphataemia in kidney failure: controversy and perspective. *Ther Adv Chronic Dis.* 2012; 3(2): 59-68.
152. Fusaro M, Tripepi G, Noale M, Vajente N, Plebani M, Zaninotto M, Guglielmi G, Miotto D, Dalle Carbonare L, D'Angelo A, Ciurlino D, Puggia R, Miozzo D, Giannini S, Gallieni M, for the EVERFRACT (Epidemiological VERtebral FRACtures iTalian Study in Dialysis) Study Investigators. High prevalence of vertebral fractures assessed by quantitative morphometry in hemodialysis patients, strongly associated with vascular calcifications. *Calcif Tissue Int* 2013; 93(1): 39-47.
153. Fusaro M, Noale M, Tripepi G, Giannini S, D'Angelo A, Pica A, Calò L, Miozzo D, Gallieni M. Long-term proton pump inhibitor use is associated with vascular calcification in chronic kidney disease: A cross-Sectional study using propensity score analysis. *Drug Safety* 2013; 36(8): 635-42.
154. Gallieni M, Molfino I. Angiotensin II, distal nephron acidification, acid retention and possibly increased ammonia levels? *Kidney Int* 2013; 83(6): 1203-4. (letter)
155. Neri L, Gallieni M, Rocca Rey LA, Bertoli SV, Andreucci V, Brancaccio D, and the MigliorDialisi Study Group. Inequalities in Transplant Waiting List Activation across Italian Dialysis Centers. *Am J Nephrol* 2013; 37(6): 575-585.
156. Lamiani G, Gallieni M, Strada I, Vegni E. Le conversazioni difficili in nefrologia [Difficult conversations in nephrology: assessment of a formative experience]. *G Ital Nefrol* 2013; 30(3).
157. Gallieni M. Book review of: "Dialysis: History, Development and Promise", Edited by Todd S. Ing, Mohamed A. Rahman, Carl M. Kjellstrand. *J Vasc Access.* 2013; 14(2):208.
158. Gallieni M, Ene-Iordache B, Aiello A, Tucci B, Sala V, Brahmochari Mandal SK, Doneda A, Stella A, Carminati S, Perico N, Genovesi S. Hypertension and kidney function in an adult population of West Bengal, India: Role of body weight, waist circumference, proteinuria and rural area living. *Nephrology (Carlton).* 2013;18(12):798-807 (PMID: 23889782) doi: 10.1111/nep.12142.
159. Mobilia F, Casali MB, Gallieni M, Genovese UR. Lethal pulmonary thromboembolism: An autopsy-based study on a rare but legally relevant event. *Med Sci Law.* 2014; 54(2): 78-83.
160. Hwang C, Davidson I, Santarelli S, Zeiler M, Ceraudo E, Pedone M, Saxena R, Slakey D, Wade M, Gallieni M. Peritoneal dialysis access: Open versus laparoscopic surgical techniques. *J Vasc Access* 2013; 14(4):307-17. doi: 10.5301/jva.5000174.
161. Bazzi C, Rizza V, Casellato D, Stivali G, Rachele G, Napodano P, Gallieni M, D'Amico G. Urinary IgG and alfa2-macroglobulin are powerful predictors of outcome and responsiveness to steroids and cyclophosphamide in idiopathic Focal Segmental Glomerulosclerosis with nephrotic syndrome. *BioMed Research International.* 2013, Article ID 941831.
162. Gallieni M, Pedone M. Left ventricular hypertrophy and serum phosphate in peritoneal dialysis patients. *Kidney Int* 2013; 84(4): 850. (letter)
163. Rossi UG, Rigamonti P, Tichà V, Zoffoli E, Giordano A, Gallieni M, Cariati M. Percutaneous ultrasound-guided central venous catheters: the lateral in-plane technique for internal jugular vein access. *J Vasc Access.* 2014; 15(1): 56-60. doi: 10.5301/jva.5000177. Epub 2013 Oct 7
164. Cupisti A, Gallieni M, Rizzo MA, Caria S, Meola M, Bolasco P. Phosphate control in dialysis. *Int J Nephrol Renovasc Dis* 2013; 6: 193-205. Review
165. Minutolo R, Locatelli F, Gallieni M, Bonofiglio R, Fuiano G, Oldrizzi L, Conte G, De Nicola L, for the REport of COMorbidities in non-dialysis Renal Disease population in ITaly (RECORD-IT) Study Group. Anemia management in non dialysis CKD patients: A multicenter prospective study in renal clinics. *Nephrol Dial Transplant* 2013; 28(12):3035-45.

166. Bertoli S, Musetti C, Ciurlino D, Basile C, Galli E, Gambaro G, Iadarola G, Guastoni C, Carlini A, Fasciolo F, Borzumati M, Gallieni M, Farina S. Peritoneal Ultrafiltration in Refractory Heart Failure: a cohort study. *Perit Dial Int* 2014 Jan-Feb;34(1):64-70. Epub 2013 Oct 31.
167. Iadarola GM, Lusardi P, La Milia V, Amici G, Santarelli S, Virga G, Basile C, Bertoli S, Bonofiglio R, Del Rosso G, Feriani M, Galli E, Gallieni M, Gambaro G, Sandrini M, Sisca S, Cancarini G. Peritoneal ultrafiltration in patients with advanced decompensated heart failure. *J Nephrol*. 2013;26 Suppl 21:159-76.
168. Fusaro M, Gallieni M, Jamal SA. Fractures in chronic kidney disease - Neglected, common and associated with sickness and death. *Kidney Int* 2014; 85(1):20-2.
169. Genovesi S, Rossi E, Pogliani D, Gallieni M, Stella A, Badiali F, Conte F, Pasquali S, Bertoli S, Ondei P, Bonforte G, Pozzi C, Valsecchi MG, Santoro A. The nephrologist's anticoagulation treatment patterns/regimens in chronic hemodialysis patients with atrial fibrillation. *J Nephrol* 2014;27(2):187-92. Epub 2014 Jan 16.
170. Maioli C, Cozzolino M, Gallieni M, Del Sole A, Tagliabue L, Strinchini A, Gaito S, Lecchi M, Cusi D, Lucignani G. Evaluation of renal function in elderly patients: performance of creatinine-based formulae versus isotopic method, the diethylene triamine pentaacetic acid (99mTc-DTPA). *Nucl Med Commun*. 2014; 35(4): 416-22.
171. Gallieni M, Aiello A, Tucci B, Sala V, Brahmochari Mandal SK, Doneda A, Genovesi S. The burden of hypertension and kidney disease in Northeast India: the Institute for Indian Mother and Child noncommunicable diseases project. *Scientific World Journal*. 2014 Jan 27;2014:320869.
172. Gallieni M, Brenna I, Brunini F, Mezzina N, Pasho S, Fornasieri A. Which cannulation technique for which patient. *J Vasc Access*. 2014 May 1;15 Suppl 7:85-90.
173. Gallieni M, Brenna I, Brunini F, Mezzina N, Pasho S, Giordano A. Dialysis central venous catheter types and performance. *J Vasc Access*. 2014 May 1;15 Suppl 7:140-6.
174. Bazzi C, Rizza V, Casellato D, Tofik R, Berg AL, Gallieni M, D'Amico G, Bakoush O. Fractional excretion of IgG in idiopathic membranous nephropathy with nephrotic syndrome: a predictive marker of risk and drug responsiveness. *BMC Nephrol*. 2014 May 8;15:74. doi: 10.1186/1471-2369-15-74.
175. Gallieni M, Fusaro M. Vitamin K and cardiovascular calcification in CKD: is patient supplementation on the horizon? *Kidney Int*. 2014 Aug;86(2):232-234.
176. Genovesi S, Gallieni M. Cardiovascular complications of calcium supplementation in chronic kidney disease: are there arrhythmic risks? *Expert Opin Drug Saf*. 2014 Sep;13(9):1143-8.
177. Ross J, Dolmatch B, Gallichio M, Gallieni M, Slakey D, Vesely T, Davidson I. Training and certification in dialysis access. *J Vasc Access*. 2014 Oct 9;15 Suppl 8:3-7.
178. Fusaro M, Gallieni M, Noale M, Tripepi G, Miozzo D, Plebani M, Zaninotto M, Guglielmi G, Miotto D, Fabris F, Piccoli A, Vilei MT, Sella S, Morachiello P, Stoppa F, Rossini M, Giannini S. The relationship between the Spine Deformity Index, biochemical parameters of bone metabolism and vascular calcifications: results from the Epidemiological VERtebral FRACtures iTalian Study (EVERFRACT) in Dialysis Patients. *Clin Chem Lab Med*. 2014 Nov;52(11):1595-603.
179. Gallieni M, Giordano A, Pinerolo C, Cariati M. Type of peritoneal dialysis catheter and outcomes. *J Vasc Access*. 2015; 16 (Suppl 9):68-72. doi: 10.5301/jva.5000369.
180. Genovesi S, Porcu L, Luise MC, Riva H, Nava E, Stella A, Pozzi C, Ondei P, Minoretta C, Gallieni M, Pontoriero G, Conte F, Torri V, Vincenti A. Mortality, sudden death and indication for cardioverter defibrillator implantation in a dialysis population. *Int J Cardiol* 2015; 186:170-177.
181. Fusaro M, Tripepi G, Noale M, Plebani M, Zaninotto M, Piccoli A, Naso A, Miozzo D, Giannini S, Avolio M, Foschi A, Rizzo MA, Gallieni M, The Vertebral Fractures And Vascular Calcifications Study

- Group. Prevalence of vertebral fractures, vascular calcifications, and mortality in warfarin treated hemodialysis patients. *Curr Vasc Pharmacol.* 2015; 13(2): 248-258.
182. Paparella M, Martina V, Rizzo MA, Gallieni M. What every doctor should know about drug safety in patients with chronic kidney disease. *Contrib Nephrol* 2015;184:24-50.
 183. Gallieni M, Cancarini G. Drugs in the elderly with chronic kidney disease: beware of potentially inappropriate medications. *Nephrol Dial Transplant.* 2015 Mar;30(3):342-4.
 184. Genovesi S, Rossi E, Gallieni M, Stella A, Badiali F, Conte F, Pasquali S, Bertoli S, Ondei P, Bonforte G, Pozzi C, Valsecchi MG, Santoro A. Warfarin use, mortality, bleeding and stroke in hemodialysis patients with atrial fibrillation. *Nephrol Dial Transplant* 2015 Mar;30(3):491-8.
 185. Porta C, Cosmai L, Gallieni M, Pedrazzoli P, Malberti F. Renal effects of targeted anticancer therapies. *Nat Rev Nephrol.* 2015; 11 (6): 354-370. doi: 10.1038/nrneph.2015.15.
 186. Rossi UG, Gallieni M, Rigamonti P, Cariati M. Retro-aortic, left inferior renal capsular vein. *Saudi J Kidney Dis Transpl* 2015; 26(4): 761-3. doi:10.4103/1319-2442.160206.
 187. Coentrão L, van Biesen W, Nistor I, Tordoir J, Gallieni M, Marti Monros A, Bolignano D. Preferred haemodialysis vascular access for diabetic chronic kidney disease patients: a systematic literature review. *J Vasc Access* 2015;16(4):259-64. doi: 10.5301/jva.5000323.
 188. Rossi UG, Rigamonti P, Torcia P, Mauri G, Brunini F, Rossi M, Gallieni M, Cariati M. Congenital anomalies of superior vena cava and their implications in central venous catheterization. *J Vasc Access.* 2015; 16:265-8.
 189. Mignani R, Gallieni M, Feriozzi S, Pisani A, Marziliano N, Morrone A. La nefropatia in corso di Malattia Di Anderson-Fabry: nuove raccomandazioni sulla diagnosi, il follow up e la terapia. [The nephropathy in the Anderson-Fabry disease: new recommendations for the diagnosis, the follow-up and the therapy]. *GIN* 2015 Jul-Aug;32(4). pii: gin/32.4.11.
 190. van der Veer SN, Haller MC, Pittens CACM, Broerse J, Castledine C, Gallieni M, Inston N, Marti Monros A, Peek N, van Biesen W. Setting priorities for optimizing vascular access decision making - an international survey of patients and clinicians. *PLOS One* 2015 Jul 7;10(7):e0128228. doi: 10.1371/journal.pone.0128228.
 191. Mudoni A, Cornacchiari M, Gallieni M, Guastoni C, McGrogan D, Logias F, Ferramosca E, Mereghetti M, Inston N. Aneurysms and pseudoaneurysms in dialysis access. *Clin Kidney J* 2015; 8(4): 363-367.
 192. Fusaro M, Dalle Carbonare L, Dusso A, Arcidiacono MV, Valenti MT, Aghi A, Pasho S, Gallieni M. Differential effects of Dabigatran and Warfarin on bone volume and structure in rats with normal renal function. *PLOS One* 2015; 10(8):e0133847.
 193. Rizzo MA, Stucchi A, Cassia MA, Gallieni M. Farmaci potenzialmente inappropriati nel paziente anziano nefropatico. [Choosing the right medications in elderly patients with chronic kidney disease]. *Recenti Progr Med* 2015;106(10):475-8.
 194. Davidson I, Gallieni M. Optimizing vascular access in the elderly: words we use affect patient care. *J Vasc Access.* 2015;16(6):437-8. doi: 10.5301/jva.5000466.
 195. Frascà GM, Sandrini S, Cosmai L, Porta C, Asch W, Santoni M, Salviani C, D'Errico A, Malvi D, Balestra E, Gallieni M. Renal cancer in kidney transplanted patients. *J Nephrol* 2015; 28(6):659-68. DOI 10.1007/s40620-015-0219-8
 196. Cosmai L, Gallieni M, Porta C. Renal toxicity of anticancer agents targeting HER2 and EGFR. *J Nephrol.* 2015 Dec;28(6):647-57.

197. Gallieni M, De Nicola L, Santoro D, Meneghel G, Formica M, Grandaliano G, Pizzarelli F, Cossu M, Segoloni G, Quintaliani G, Di Giulio S, Pisani A, Malaguti M, Marseglia C, Oldrizzi L, Pacilio M, Conte G, Canton AD, Minutolo R. Management of CKD-MBD in non-dialysis patients under regular nephrology care: a prospective multicenter study. *J Nephrol.* 2016;29(1):71-8. doi: 10.1007/s40620-015-0215-z.
198. Fusaro M, Giannini S, Gallieni M, Noale M, Tripepi G, Rossini M, Messa P, Rigotti P, Pati T, Barbisoni F, Piccoli A, Aghi A, Alessi M, Bonfante L, Fabris F, Zambon S, Sella S, Plebani M. Calcimimetic and Vitamin D Analog use in hemodialyzed patients is associated with increased levels of Vitamin K Dependent Proteins. *Endocrine* 2016;51(2):333-41. doi: 10.1007/s12020-015-0673-z.
199. Rossi UG, Torcia P, Rigamonti P, Colombo F, Giordano A, Gallieni M, Cariati M. Tunnelled central venous catheter exchange: techniques to improve prevention of air embolism. *J Vasc Access.* 2016;17(2):200-3. doi: 10.5301/jva.5000483.
200. Gallieni M, Giordano A, Rossi U, Cariati M. Optimization of dialysis catheter function. *J Vasc Access.* 2016;17 Suppl 1:42-6. doi: 10.5301/jva.5000538.
201. Davidson I, Dolmatch B, Gallieni M, Ho P, Kraines K, Liew NC, Parakh R, Ross J, Slakey D. Training in dialysis access - charting future success. *J Vasc Access.* 2016;17 Suppl 1:47-52. doi: 10.5301/jva.5000528.
202. Cosmai L, Porta C, Gallieni M, Perazella MA. Onco-Nephrology: A Decalogue. *Nephrol Dial Transplant.* 2016 Apr;31(4):515-9. doi: 10.1093/ndt/gfv320. Review.
203. Pani A, Porta C, Cosmai L, Melis P, Floris M, Piras D, Gallieni M, Rosner M, Ponticelli C. Glomerular diseases and cancer: evaluation of underlying malignancy. *J Nephrol* 2016; 29: 143-152. doi: 10.1007/s40620-015-0234-9.
204. Frascà GM, D'Errico A, Malvi D, Porta C, Cosmai L, Santoni M, Sandrini S, Salviani C, Gallieni M, Balestra E. Transplantation of kidneys with tumors. *J Nephrol.* 2016 Apr;29(2):163-8. doi: 10.1007/s40620-015-0249-2.
205. Lomonte C, Forneris G, Gallieni M, Tazza L, Meola M, Lodi M, Senatore M, Morale W, Spina M, Napoli M, Bonucchi D, Galli F, On behalf of the Vascular Access Working Group of the Italian Society of Nephrology. The vascular access in the elderly: a position statement of the Vascular Access Working Group of the Italian Society of Nephrology. *J Nephrol* 2016 Apr;29(2):175-84. doi: 10.1007/s40620-016-0263-z.
206. Ene-lordache B, Perico N, Bikbov B, Carminati S, Remuzzi A, Perna A, Islam N, Bravo RF, Aleckovic-Halilovic M, Zou H, Zhang L, Gouda Z, Tchokhnelidze I, Abraham G, Mahdavi-Mazdeh M, Gallieni M, Codreanu I, Togtokh A, Sharma SK, Koirala P, Uprety S, Ulasi I, Remuzzi G. Chronic kidney disease and cardiovascular risk in six regions of the world (ISN-KDDC): a cross-sectional study. *Lancet Global Health* 2016;4(5):e307-19. doi: 10.1016/S2214-109X(16)00071-1.
207. Fusaro M, Giannini S, Gallieni M. Adverse effects of proton pump inhibitors in chronic kidney disease. *JAMA Int Med* 2016; 176(6):866. (letter)
208. Fusaro M, Gallieni M, Rebora P, Rizzo MA, Luise MC, Riva H, Bertoli S, Conte F, Stella A, Ondeì P, Rossi E, Valsecchi MG, Santoro A, Genovesi S. Atrial fibrillation and low vitamin D levels are associated with severe vascular calcifications in a population of hemodialysis patients. *J Nephrol* 2016 Jun;29(3):419-26. doi: 10.1007/s40620-015-0236-7.
209. Porta C, Cosmai L, Gallieni M, Perazella MA. Harmonization of renal function assessment is needed throughout the whole process of anticancer drug development. *J Clin Oncol* 2016 May 16. pii: JCO670786. [Epub ahead of print] - (letter)
210. Parisotto MT, Pelliccia F, Bedenbender-Stoll E, Gallieni M. Haemodialysis plastic cannulae - a possible alternative to traditional metal needles? *J Vasc Access* 2016;17(5):373-9. doi: 10.5301/jva.5000594

211. Mudoni A, Caccetta F, Caroppo M, Musio F, Accogli A, Zacheo MD, Burzo MD, Gallieni M, Nuzzo V. Color Doppler ultrasound: a valuable diagnostic tool in the assessment of arterio-venous fistula status in hemodialysis patients. *J Vasc Access* 2016; 17(5):373-379 doi: 10.5301/jva.5000588.
212. Mignani R, Pieruzzi F, Berri F, Burlina A, Chinae B, Gallieni M, Pieroni M, Salviati A, Spada M. FABry STabilization indEX (FASTEx): an innovative tool for the assessment of clinical stabilization in Fabry disease. *Clin Kidney J* 2016;9(5):739-47. doi: 10.1093/ckj/sfw082.
213. Brunini F, Page TH, Gallieni M, Pusey CD. The role of monocytes in ANCA-associated vasculitides. *Autoimmun Rev.* 2016 Nov;15(11):1046-1053. doi: 10.1016/j.autrev.2016.07.031.
214. Fabbrini P, Finkel K, Gallieni M, Capasso G, Cavo M, Santoro A, Pasquali S. Light chains removal by extracorporeal techniques in acute kidney injury due to multiple myeloma. *J Nephrol* 2016 Dec;29(6):735-746
215. Gallieni M, Cupisti A. DASH and Mediterranean diets as nutritional interventions for Chronic Kidney Disease patients. *Am J Kidney Dis* 2016;68(6):828-830. doi: 10.1053/j.ajkd.2016.09.001.
216. Genovesi S, Porcu L, Luise MC, Riva H, Nava E, Contaldo G, Stella A, Pozzi C, Ondeì P, Minorette C, Gallieni M, Pontoriero G, Conte F, Torri V, Bertoli SV, Vincenti A. Sudden death in end stage renal disease: Comparing hemodialysis versus peritoneal dialysis. *Blood Purif.* 2017;44(1):77-88.
217. Fusaro M, Plebani M, Iervasi G, Gallieni M. Vitamin K deficiency in chronic kidney disease: evidence is building up. *Am J Nephrol* 2017;45(1):1-3. DOI: 10.1159/000451070
218. Davidson I, Beathard G, Gallieni M, Ross J. The DRIL procedure for arteriovenous access ischemic steal: a controversial approach. *J Vasc Access.* 2017 Jan 18;18(1):1-2. doi: 10.5301/jva.5000628.
219. Gallieni M, Messa P. A survival benefit with phosphate binding treatment in CKD patients cannot be excluded. (Letter to the Editor). *Am J Kidney Dis* 2017; 69(3):481-482. doi: 10.1053/j.ajkd.2016.10.041.
220. Gallieni M, Giordano A, Ricchiuto A, Gobatti D, Cariati M. Dialysis access: issues related to conversion from peritoneal dialysis to hemodialysis and vice versa. *J Vasc Access.* 2017 Mar 6;18(Suppl. 1):41-46. doi: 10.5301/jva.5000695.
221. Rossi UG, Gallieni M, Cariati M. Response to: Central venous catheterization in fragile patients: which is the best approach? *J Vasc Access.* 2017 Mar 21;18(2):e25. Feb 3:0. doi: 10.5301/jva.5000667.
222. Cosmai L, Gallieni M, Liguigli W, Porta C. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). *J Nephrol.* 2017 Apr;30(2):171-180. Review
223. Fusaro M, D'Alessandro C, Noale M, Tripepi G, Plebani M, Veronese N, Iervasi G, Giannini S, Rossini M, Tarroni G, Lucatello S, Vianello A, Santinello I, Bonfante L, Fabris F, Sella S, Piccoli A, Naso A, Ciurlino D, Aghi A, Gallieni M, Cupisti A. Low vitamin K1 intake in hemodialysis patients. *Clin Nutr* 2017 Apr;36(2):601-607. doi: 10.1016/j.clnu.2016.04.024.
224. Cupisti A, D'Alessandro C, Gesualdo L, Cosola C, Gallieni M, Egidi MF, Fusaro M. Non-traditional aspects of renal diets: focus on fiber, alkali and vitamin K intake. *Nutrients* 2017 Apr 29;9(5). pii: E444. doi: 10.3390/nu9050444.
225. Fusaro M, Gallieni M, Rizzo MA, Stucchi A, Delanaye P, Cavalier E, Moysés MR, Jorgetti V, Giannini S, Fabris F, Aghi A, Sella S, Galli F, Viola V, Plebani M. Vitamin K plasma levels determination in human health. *Clin Chem Lab Med.* 2017 May 1;55(6):789-799. doi: 10.1515/cclm-2016-0783.

226. Fusaro M, Mereu MC, Aghi A, Iervasi G, Gallieni M. Vitamin K and bone. *Clinical Cases Miner Bone Metab* 2017 May-Aug;14(2):200-206. doi: 10.11138/ccmbm/2017.14.1.200.
227. Genovesi S, Antolini L, Orlando A, Brahmochari SK, De Servi A, Capelli S, Giussani M, Nava E, Agostoni C, Gallieni M. Poor early growth and high salt intake in Indian infants *Int J Food Sci Nutr* 2017 Jun;68(4):467-472. doi: 10.1080/09637486.2016.1249463.
228. Davidson I, Beathard G, Gallieni M, Ross J. Authors' response to comments on: The DRIL procedure for arteriovenous access ischemic steal: a controversial approach. *J Vasc Access*. 2017 Jul 26:0. doi: 10.5301/jva.5000758.
229. Genovesi S, Rebora P, Gallieni M, Stella A, Badiali F, Conte F, Pasquali S, Bertoli S, Ondei P, Bonforte G, Pozzi C, Rossi E, Valsecchi MG, Santoro A. Effect of oral anticoagulant therapy on mortality in end stage renal disease patients: a prospective study. *J Nephrol* 2017 Aug;30(4):573-581. doi: 10.1007/s40620-016-0364-8.
230. Rossi UG, Gallieni M, Cariati M. Response to: The role of interventional radiology in detecting abnormalities of the superior vena cava anatomy. *J Vasc Access*. 2017 Aug 2:0. doi: 10.5301/jva.5000789.
231. Fusaro M, Gallieni M, Aghi A, Iervasi G, Rizzo MA, Stucchi A, Noale M, Tripepi G, Nickolas T, Veronese N, Fabris F, Giannini G, Calò L, Piccoli A, Mereu MC, Cosmai L, Ferraro A, Magonara F, Spinello M, Sella S, Plebani M. Cigarette smoking is associated with decreased Bone Gla-protein (BGP) levels in hemodialysis patients. *Current Vasc Pharmacol* 2017 Sep 19. doi: 10.2174/1570161115666170919182421.
232. Cassia M, Alberici F, Gallieni M, Jayne D. Lupus nephritis and B cell targeting therapy. *Expert Rev Clin Immunol* 2017 Oct;13(10):951-962. DOI: 10.1080/1744666X.2017.1366855.
233. Rossi UG, Gallieni M, Cariati M. Response to: The role of ultrasound evaluation in central venous catheter exchange. *J Vasc Access*. 2017 Nov 17;18(6):e104. doi: 10.5301/jva.5000719.
234. Gallieni M. In memoriam Seiji Ohira (1937-2017). *J Vasc Access*. 2017 Nov 17;18(6):e118.
235. Genovesi S, Nava E, Pasa A, Corghi E, Ondei P, Marta E, Bellasi A, Malberti F, Teatini U, Guastoni CM, Spatola L, Luise MC, Tiboldo R, Bertoli S, Messa P, Doria M, Gallieni M, Cozzolino M, Spotti D, Sala V, Sironi E, Boriani G. Clinical practice for the diagnosis of cardiac arrhythmias in patients on renal replacement therapy: data from a Lombard survey. *G Ital Nefrol*. 2017 Dec 5;34(Nov-Dec). pii: 2017-vol6. Italian.
236. Gallieni M, Cosmai L, Porta C. Acute kidney injury in cancer patients. *Contrib Nephrol*. 2018; 193:137-148.
237. Bazzi C, Usui T, Rizza V, Casellato D, Gallieni M, Nangaku M. Urinary N-acetyl-β-glucosaminidase and eGFR may identify patients to be treated with immuno-suppression at diagnosis in idiopathic membranous nephropathy. *Nephrology* 2018; 23: 175-182. doi: 10.1111/nep.12952.
238. Tordoir JHM, Zonnebeld N, van Loon M, Gallieni M, Hollenbeck M. Surgical and endovascular intervention for dialysis access maturation failure after arteriovenous fistula surgery: review of the evidence. *Eur J Vasc Endovasc Surg*. 2018;55(2):240-248. doi: 10.1016/j.ejvs.2017.12.001
239. Davidson I, Beathard G, Gallieni M, Ross J. Authors' response to Comments on: The DRIL procedure for arteriovenous access ischemic steal: a controversial approach. *J Vasc Access*. 2018; 19(2):211. doi: 10.5301/jva.5000758.
240. Viecelli AK, Tong A, O'Lone E, Ju A, Hanson CS, Sautenet B, Craig JC, Manns B, Howell M, Chemla E, Hooi LS, Johnson DW, Lee T, Lok CE, Polkinghorne KR, Quinn RR, Vachharajani T, Vanholder R, Zuo L, Hawley CM; SONG-HD Vascular Access Workshop Investigators (Levin A, Tong A, Viecelli A, Ju A, Wang A, Porter A, Sautenet B, Reddy B, Manns B, Hemmelgarn B, Schiller B, Hanson C, Hawley C, Lok C, Wheeler D, Harris D, Johnson D, Schatell D, Lacson E Jr., Bavlovlenskoy E, O'Lone E, Chemla E,

- Caskey F, Strippoli G, Feldman H, Apata I, Tordoir J, Flythe J, Gill J, Kusek J, Craig J, Polkinghorne K, Abbott K, Hooi LS, Dember L, Zuo L, Cervantes L, Moist L, Poole L, Tonelli M, Howell M, Gallieni M, Elliot M, Klusmeyer M, Josephson M, Robbin M, Riella M, Evangelidis N, Tugwell P, Kerr P, Ravani P, Roy-Chaudhury P, Mehrotra R, Vanholder R, Quinn R, Pecoits-Filho R, Crowe S, Evered S, Segerer S, Fadem S, McDonald S, Sprague S, Palmer S, Poma T, Lee T, Vachharajani T, Sikirica V, Jha V, van Biesen W, Winkelmayer W, Mayers A, Bell B, Carter J, Hardy K, Ennis M, Johnson M, Rouse N Jr., Wright S, Harris T, Muhammad U, McNorton V, Mayers D, Ennis D.). Report of the Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) Consensus Workshop on Establishing a Core Outcome Measure for Hemodialysis Vascular Access. *Am J Kidney Dis* 2018; 71(5): 690-700. doi: 10.1053/j.ajkd.2017.12.003
241. Fusaro M, Cannata JB, Nickolas TL, Plebani M, Mereu MC, Aghi A, Gallieni M. Clinical relevance and future perspective of fractures in patients with CKD. *Kidney Int* 2018; 93(5):1248. doi: 10.1016/j.kint.2018.02.012. (letter)
242. Schmidli J, Widmer MK, Basile C, De Donato G, Gallieni M, Gibbons CP, Haage P, Hamilton G, Hedin U, Kamper L, Lazarides MK, Lindsey B, Mestres G, Pegoraro M, Roy J, Setacci C, Shemesh D, Tordoir JHM, van Loon M. Vascular Access Clinical Practice Guidelines of the European Society for Vascular Surgery. *Eur J Vasc Endovasc Surg* 2018 Jun;55(6):757-818. doi: 10.1016/j.ejvs.2018.02.001.
243. Cosmai L, Porta C, Perazella MA, Launay-Vacher V, Rosner MH, Jhaveri KD, Floris M, Pani A, Teuma C, Szczylik CA, Gallieni M. Opening an onconeurology clinic: recommendations and basic requirements. *Nephrol Dial Transplant*. 2018 Sep 1;33(9):1503-1510. doi: 10.1093/ndt/gfy188.
244. Cupisti A, Gallieni M. Urinary Phosphorus Excretion: Not what we have believed it to be? *Clin J Am Soc Nephrol* 2018;13(7):973-974. doi: 10.2215/CJN.06260518.
245. Alfieri C, Malberti F, Mazzaferro S, Gallieni M, Russo D, Messa P, Cozzolino M. [Hyperphosphatemia in dialysis: which binder?] Iperfosfatemia in dialisi: la scelta del chelante. *Giorn Ital Nefrol* 2018 Sep;35(5). pii: 2018-vol5. Italian.
246. Piccoli GB, Cabiddu G, Gallieni M. Patients' wishes, pregnancy and vascular access: when one size does not fit all. *J Vasc Access* 2018; 19(6):518-520. doi: 10.1177/1129729818809896.
247. Finkel K, Gallieni M. Extracorporeal removal of light chains: new data and continued controversies. *Clin J Am Soc Nephrol*. 2018; 13(11):1753-1754. doi: 10.2215/CJN.05100418. (IF 5.83)
248. Savoj J, Becerra B, Kim JL, Fusaro M, Gallieni M, Lombardo D, Lau WL. Utility of cardiac biomarkers in the setting of kidney disease. *Nephron*. 2019;141(4):227-235. doi: 10.1159/000495946.
249. Rossi UG, Rollandi GA, Ierardi AM, Valdata A, Pinna F, Pescatori LC, Gallieni M, Carrafiello G, Cariati M. Materials and techniques for percutaneous retrieval of intravascular foreign body. *J Vasc Access*. 2019 Jan;20(1):87-94. doi: 10.1177/1129729818785051.
250. Vertemati M, Cassin S, Rizzetto F, Vanzulli A, Elli M, Sampogna G, Gallieni M. A virtual reality environment to visualize 3D patient-specific models by a mobile head-mounted display. *Surg Innov*. 2019 Jun;26(3):359-370. doi: 10.1177/1553350618822860.
251. Frascà GM, Brigante F, Volpe A, Cosmai L, Gallieni M, Porta C. Kidney transplantation in patients with previous renal cancer: a critical appraisal of current evidence and guidelines. *J Nephrol*. 2019 Feb;32(1):57-64. doi: 10.1007/s40620-018-0542-y.
252. Fusaro M, Gallieni M, Aghi A, Rizzo A, Iervasi G, Nickolas TL, Fabris F, Mereu MC, Giannini S, Sella S, Giusti A, Pitino A, D'Arrigo A, Rossini M, Gatti D, Ravera M, Di Lullo L, Piccoli A, Tripepi G, Plebani M. Osteocalcin (bone GLA protein) levels, vascular calcifications, vertebral fractures and mortality in hemodialysis patients with diabetes mellitus. *J Nephrol*. 2019 Aug;32(4):635-643. doi: 10.1007/s40620-019-00595-1.
253. Tozzi M, Gallieni M. Antiplatelet therapy for prevention of hemodialysis vascular access thrombosis and improving survival. *J Nephrol*. 2019;32(4):491-493. doi: 10.1007/s40620-019-00598-y.

254. Porta C, Cosmai L, Leibovich B, Powles T, Gallieni M, Bex A. The adjuvant treatment of kidney cancer: a multidisciplinary outlook. *Nat Rev Nephrol.* 2019 Jul;15(7):423-433. doi: 10.1038/s41581-019-0131-x.
255. Chan C, Blankestijn PJ, Dember LM, Gallieni M, Harris D, Lok CE, Mehrotra R, Stevens P, Wang AYM, Cheung M, Wheeler DC, Winkelmayr WC, Pollock C, for Conference Participants. Dialysis initiation, modality choice, access, and prescription: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) controversies conference. *Kidney Int* 2019 Jul;96(1):37-47. doi: 10.1016/j.kint.2019.01.017.
256. Cassia MA, Alberici F, Jones RB, Smith RM, Casazza G, Urban ML, Emmi C, Moroni G, Sinico RA, Messa P, Vaglio A, Hall F, Gallieni M, Jayne DR. Rituximab as maintenance treatment for systemic lupus erythematosus: a multicentre observational study of 147 patients. *Arthritis Rheumatol* 2019 Oct;71(10):1670-1680. doi: 10.1002/art.40932.
257. Fila B, Roca-Tey R, Malik J, Malovrh M, Pirozzi N, Kuzstal M, Gallieni M, Jemcov T. Quality assessment of vascular access procedures for hemodialysis: a position paper of the Vascular Access Society. *J Vasc Access* 2020 Mar;21(2):148-153. doi: 10.1177/1129729819848624
258. Gallieni M, Hollenbeck M, Inston N, Kumwenda M, Powell S, Tordoir J, Al Shakarchi J, Berger P, Bolignano D, Cassidy D, Chan TY, Dhondt A, Drechsler C, Ecder T, Finocchiaro P, Haller M, Hanko J, Heye S, Ibeas J, Jemcov T, Kershaw S, Khawaja A, Labriola L, Lomonte C, Malovrh M, Marti I Monros A, Matthew S, McGrogan D, Meyer T, Mikros S, Nistor I, Planken N, Roca-Tey R, Ross R, Troxler M, van der Veer S, Vanholder R, Vermassen F, Welander G, Wilmink T, Koobasi M, Fox J, Van Biesen W, Nagler E. Clinical practice guideline on peri- and postoperative care of arteriovenous fistulas and grafts for haemodialysis in adults. *Nephrol Dial Transplant.* 2019 Jun 1;34(Supplement_2): ii1-ii42. doi: 10.1093/ndt/gfz072.
259. Tedesco M, Gallieni M, Pellegata F, Cozzolino M, Alberici F. Update on ANCA-associated vasculitis: from biomarkers to therapy. *J Nephrol* 2019 Dec;32(6):871-882. doi: 10.1007/s40620-019-00628-9.
260. Fusaro M, Darrigo G, Pitino A, Iervasi G, Tentori F, Robinson B, Aghi A, Bieber B, McCulloch K, Fabris F, Plebani M, Gallieni M, Tripepi G. Increased risk of bone fractures in hemodialysis patients treated with proton pump inhibitors: results from the Dialysis Outcomes and Practice Patterns study (DOPPS). *J Bone Miner Res.* 2019 Dec;34(12):2238-2245. doi: 10.1002/jbmr.3842.
261. Ibeas J, Malik J, Gallieni M. Endorsement and evaluation of dialysis access guidelines from the standpoint of the Vascular Access Society. *J Vasc Access* 2020 Jan;21(1):4-6. doi: 10.1177/1129729819867514.
262. Capasso A, Benigni A, Capitanio U, Danesh FR, Di Marzo V, Gesualdo L, Grandaliano G, Jaimes EA, Malyszko J, Perazella MA, Qian Q, Ronco P, Rosner MH, Trepiccione F, Viggiano D, Zoccali C, Capasso G, Akitaka A, Alahoti A, Alexander TR, Altucci L, Amer H, Barone V, Biancone L, Bonventre JV, Camussi G, Ciardiello F, Caraglia M, Carteni G, Cervantes A, Citterio F, Cosmai L, Daniele B, D'Errico A, De Vita F, Ereditato A, Falco G, Fouque D, Franco R, Gallieni M, Gambaro G, Kuo C, Launay-Vacher V, Maiello E, Mallamaci F, Marino G, Martinelli E, Matarese G, Matsubara T, Messa P, Messina C, Mirone V, Morgillo F, Costa AN, Orditura M, Pani A, Perna A, Pisano C, Pitts T, Porta C, Procopio G, Remuzzi G, Russo D, Siu LL, Stadler W, Troiani T, Weisz A, Więcek A, Xiaoqiang D, Zecchino O. Summary of the International Conference on Onco-Nephrology: an emerging field in medicine. *Kidney Int.* 2019 Sep;96(3):555-567. doi: 10.1016/j.kint.2019.04.043. IF 8.306
263. Camerotto C, Cupisti A, D'Alessandro C, Muzio F, Landriani N, Gallieni M. Dietary fiber and gut microbiota in renal diets. *Nutrients.* 2019;11(9):2149. doi: 10.3390/nu11092149.
264. Fusaro M, Holden R, Lok C, Iervasi G, Plebani M, Aghi A, Gallieni M, Cozzolino M. Phosphate and bone fracture risk in chronic kidney disease patients. *Nephrol Dial Transplant* 2021 Feb 20;36(3):405-412. doi: 10.1093/ndt/gfz196

265. Cupisti A, Piccoli GB, Gallieni M. Charcoal for the management of pruritus and uremic toxins in patients with CKD. *Curr Opin Nephrol Hypertens* 2020;29(1):71-79. doi: 10.1097/MNH.0000000000000567.
266. Fusaro M, Gallieni M, Porta C, Nickolas TL, Khairallah P. Vitamin K effects in human health: new insights beyond bone and cardiovascular health. *J Nephrol.* 2020 Apr;33(2):239-249. doi:10.1007/s40620-019-00685-0
267. Vertemati M, Rizzetto F, Cassin S, Zerbi P, Giordano A, Cariati M, Gallieni M. Clinical relevance of the left brachiocephalic vein anatomy for vascular access in dialysis patients. *Clin Anat.* 2020 Nov;33(8):1120-1129. doi:10.1002/ca.23549.
268. Ravera M, Nickolas T, Plebani M, Iervasi G, Aghi A, Khairallah P, Gallieni M, Mereu MC, Giannini S, Sella S, Zaninotto M, Paoletti E, Bussalino E, Di Lullo L, Bellasi A, Cosmai L, Foramitti M, Malberti F, Brandi ML, Ferrari S, Tripepi G, Fusaro M. Overweight - obesity is associated with decreased vitamin K2 levels in hemodialysis patients. *Clin Chem Lab Med* 2020 May 8;59(3):581-589. doi:10.1515/cclm-2020-0194
269. Gallieni M, Buskermolen M, Boggio A, De Salvo C, Camerotto C. Plant-based kidney diets prescribed in nutrition clinics: clinical advantages with low risks of hyperkalemia. *Int Emerg Med* 2021 Jan;16(1):23-24. doi: 10.1007/s11739-020-02363-7.
270. Genovesi S, Porcu L, Slaviero G, Casu G, Bertoli S, Sagone A, Buskermolen M, Pieruzzi F, Rovaris G, Montoli A, Oreglia J, Piccaluga E, Molon G, Gaggiotti M, Etori F, Gaspardone A, Palumbo R, Viazzi F, Breschi M, Gallieni M, Contaldo G, D'Angelo G, Merella P, Galli F, Rebora P, Valsecchi M, Mazzone P. Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis [published correction appears in *J Nephrol.* 2021 Feb;34(1):75-76]. *J Nephrol.* 2021 Feb;34(1):63-73. doi:10.1007/s40620-020-00774-5.
271. Granata A, Maccarrone R, Di Lullo L, Morale W, Battaglia GG, Di Nicolò P, Bellasi A, Pesce F, Khater E, Gesualdo L, Basile A, Gallieni M. Feasibility of routine ultrasound-guided percutaneous transluminal angioplasty in the treatment of native arteriovenous fistula dysfunction. *J Vasc Access.* 2020 Jul 25;1129729820943076. doi: 10.1177/1129729820943076. Epub ahead of print.
272. Fusaro M., Cosmai L, Evenepoel P, Nickolas TL, Cheung A, Aghi A, Tripepi G, Plebani M, Iervasi G, Vettor R, Zaninotto M, Ravera M, Foramitti M, Giannini S, Sella S, Gallieni M. Vitamin K and kidney transplantation. *Nutrients* 2020; 12: 2717; doi:10.3390/nu12092717
273. Gallieni M, Matoussevitch V, Cariati M, Ebner A, Gallo S, Sengölge G, Steinke T. Multicenter experience with the Surfacor® Inside-Out® Access Catheter System in Patients with Thoracic Venous Obstruction: Results from the SAVE Registry. *J Vasc Interv Radiol.* 2020;31(10):1654-1660.e1. doi: 10.1016/j.jvir.2020.06.020
274. Malyszko J, Bamias A, Danesh F, Dębska-Ślizień A, Gallieni M, Gertz M, Kielstein J, Tesarova P, Wong G, Cheung M, Wheeler DC, Winkelmayer WC, Porta C, for Conference Participants. Understanding kidney impairment and solid-organ malignancies and managing kidney cancer: Conclusions from the Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference on Onconeurology. *Kidney Int* 2020;98(5):1108-1119. doi: 10.1016/j.kint.2020.06.046.
275. Malik J, Lomonte C, Rotmans J, Chytilova E, Roca-Tey R, Kuzstal M, Grus T, Gallieni M. Hemodialysis vascular access affects cardiac function and outcomes: tips for choosing the right access for the individual patient. *J Vasc Access.* 2020 Nov 4;1129729820969314. doi: 10.1177/1129729820969314. Online ahead of print.
276. Fusaro M, Cozzolino M, Plebani M, Iervasi G, Ketteler M, Gallieni M, Aghi A, Locatelli F, Cunningham J, Syazrah S, Zaninotto M, Ravera M, Russo D, Mereu MC, Giannini S, Brandi ML, Sella S, Bellasi A, Di Lullo L, Tripepi G, Nickolas T. Sevelamer use, vitamin K levels, vascular calcifications and vertebral fractures in hemodialysis patients: results from the VIKI study. *J Bone Mineral Res.* 2021 Mar;36(3):500-509. doi: 10.1002/jbmr.4214.

277. Cupisti A, Gallieni M, Avesani CM, D'Alessandro C, Carrero JJ, Piccoli GB. Medical nutritional therapy for patients with chronic kidney disease not on dialysis: low protein diet as a medication. *J. Clin. Med.* 2020;9:E3644. doi:10.3390/jcm9113644.
278. Cosmai L, Porta C, Foramitti M, Rizzo M, Gallieni M. The basics of onco-nephrology in the renal clinic. *J Nephrol.* 2020;33(6):1143-1149. doi: 10.1007/s40620-020-00922-x.
279. Fusaro M, Cianciolo G, Brandi ML, Ferrari S, Nickolas TL, Tripepi G, Plebani M, Zaninotto M, Iervasi G, La Manna G, Gallieni M, Vettor R, Aghi A, Gasperoni L, Giannini S, Sella S, Cheung AM. Vitamin K and Osteoporosis. Fusaro M, Cianciolo G, Brandi ML, Ferrari S, Nickolas TL, Tripepi G, Plebani M, Zaninotto M, Iervasi G, La Manna G, Gallieni M, Vettor R, Aghi A, Gasperoni L, Giannini S, Sella S, Cheung AM. Vitamin K and Osteoporosis. *Nutrients* 2020, 12:E3625; <https://doi.org/10.3390/nu12123625>.
280. Małyszko J, Bamias A, Danesh FR, Dębska-Ślizień A, Gallieni M, Gertz MA, Kielstein JT, Tesarova P, Wong G, Cheung M, Wheeler DC, Winkelmayer WC, Porta C; Conference Participants. KDIGO Controversies Conference on onco-nephrology: kidney disease in hematological malignancies and the burden of cancer after kidney transplantation. *Kidney Int.* 2020 Dec;98(6):1407-1418. doi: 10.1016/j.kint.2020.07.012. PMID: 33276867.
281. Panuccio V, Mallamaci F, Pizzini P, Tripepi R, Garofalo C, Parlongo G, Caridi G, Provenzano M, Mafrica A, Simone G, Cutrupi S, D'Arrigo G, Porto G, Tripepi G, Nardellotto A, Meneghel G, Dattolo P, Pizzarelli F, Rapisarda F, Ricchiuto A, Fatuzzo P, Verdesca S, Gallieni M, Gesualdo L, Conte G, Plebani M, Zoccali C. Reducing salt intake by urine chloride self-measurement in non-compliant patients with chronic kidney disease followed in nephrology clinics: a randomized trial. *Nephrol Dial Transplant.* 2020 Dec 8:gfaa262. doi: 10.1093/ndt/gfaa262. Epub ahead of print.
282. Heidempergher M, Sabiu G, Orani MA, Tripepi G, Scorza D, Gallieni M. Targeting COVID-19 prevention in hemodialysis facilities is associated with a drastic reduction of central venous catheter related infections. *J Nephrol* 2021 Apr;34(2):345-353. doi: 10.1007/s40620-020-00900-3.
283. Nordio M, Reboldi G, Di Napoli A, Quintaliani G, Alberici F, Postorino M, Aucella F, Messa P, Brunori G; Italian Society of Nephrology COVID-19 Research Group. Risk factors and action thresholds for the novel coronavirus pandemic. Insights from the Italian Society of Nephrology COVID-19 Survey. *J Nephrol.* 2021 Apr;34(2):325-335. doi: 10.1007/s40620-020-00946-3.
284. Cosmai L, Porta C, Foramitti M, Perrone V, Mollica L, Gallieni M, Capasso G. Preventive strategies of acute kidney injury in cancer patients. *Clin Kidney J* 2020;14(1):70-83. doi: 10.1093/ckj/sfaa127.
285. Sahay M, Jasuja S, Tang SCW, Alexander S, Jha V, Vachharajani T, Mostafi M, Pisharam JK, Jacob C, Gunawan A, Bak Leong G, Thwin KT, Agrawal RK, Vareesangthip K, Tanchanco R, Choong L, Herath C, Lin CC, Cuong NT, Haian HP, Akhtar SF, Alsahow A, Rana DS, Rajapurkar MM, Kher V, Verma S, Ramachandran R, Bhargava V, Puri S, Sagar G, Bahl A, Mandal S, Gupta A, Gallieni M. Aetiology, practice patterns and burden of end-stage kidney disease in South Asia and South-East Asia: A questionnaire-based survey. *Nephrology (Carlton).* 2021;26(2):142-152. doi: 10.1111/nep.13825.
286. Gallieni M, De Salvo C, Lunati ME, Rossi A, D'Addio F, Pastore I, Sabiu G, Miglio R, Zuccotti GV, Fiorina P. Continuous glucose monitoring in patients with diabetes on hemodialysis. *Acta Diabetol.* 2021 Mar 20. doi: 10.1007/s00592-021-01699-6. Online ahead of print.
287. Nardelli L, Scalamogna A, Pisati S, Gallieni M, Messa P. [Urgent-start PD: a viable approach]. *G Ital Nefrol.* 2021;38(2):2021-vol2. Italian.
288. Gallieni M, Fiorina P, Paik JM. Polypill, cardiovascular outcomes and progression of kidney disease. *New Engl J Med* 2021;384(17):1673-1674. doi: 10.1056/NEJMc2102972. (letter)
289. Ramachandran R, Bhargava V, Jasuja S, Gallieni M, Jha V, Sahay M, Alexander S, Mostafi M, Pisharam JK, Chi Wai TS, Jacob C, Gunawan A, Leong GB, Thwin KT, Agrawal RK, Vareesangthip K,

Tanchanco R, Choong L, Herath C, Lin CC, Cuong NT, Akhtar SF, Alsahow A, Rana DS, Rajapurkar MM, Kher V, Jeyaseelan L, Puri S, Sagar G, Bahl A, Verma S, Sethi A, Vachharajani T. Interventional nephrology and vascular access practice: A perspective from South and Southeast Asia. *J Vasc Access*. 2021 May 3;11297298211011375. doi: 10.1177/11297298211011375. Epub ahead of print

290. Ferretti F, Cannatelli R, Benucci M, Carmagnola S, Clementi E, Danelli P, Dilillo D, Fiorina P, Galli M, Gallieni M, Genovese G, Giorgi V, Invernizzi A, Maconi G, Maier JA, Marzano AV, Morpurgo PS, Nebuloni M, Radovanovic D, Riva A, Rizzardini G, Sabiu G, Santus P, Staurengi G, Zuccotti G, Sarzi-Puttini PC, Ardizzone S. How to Manage COVID-19 Vaccination in Immune-Mediated Inflammatory Diseases: An Expert Opinion by IMIDs Study Group. *Front Immunol*. 2021 Apr 15;12:656362. doi: 10.3389/fimmu.2021.656362.

291. Alexander S, Jasuja S, Gallieni M, Sahay M, Rana DS, Jha V, Verma S, Ramachandran R, Bhargava V, Sagar G, Bahl A, Mostafi M, Pisharam J, Tang SCW, Jacob C, Gunawan A, Leong GB, Thwin KT, Agrawal R, Vareesangthip K, Tanchanco R, Choong L, Herath C, Lin C, Cuong N, Haian HP, Akhtar F, AlSahow A, Rajapurkar MM, Kher V, Mehta HJ, Bhalla A, Khanna U, Ray DS, Puri S, Jain H, Lydia A, Vachharajani T. Impact of National Economy and Policies on End Stage Kidney Care in South Asia and Southeast Asia. *Int J Nephrol* 2021 May 6; 2021:6665901. doi: 10.1155/2021/6665901.

292. Loretelli C, Rocchio F, D'Addio F, Ben Nasr M, Castillo-Leon E, Dellepiane S, Vergani A, Abdelsalam A, Assi E, Maestroni A, Usueli V, Bassi R, Pastore I, Yang J, El Essawy B, Elased KM, Fadini GP, Ippolito E, Seelam AJ, Pezzolesi M, Corradi D, Zuccotti GV, Gallieni M, Allegretti M, Niewczas MA, Fiorina P. The IL-8-CXCR1/2 axis contributes to diabetic kidney disease. *Metabolism* 2021 June 4: 154804. doi: 10.1016/j.metabol.2021.154804.

293. Mitra S, Jayanti A, Vart P, Cocca A, Gallieni M, Øvrehus MA, Midtved K, ElHafeez SA, Gandolfini I, Büttner S, Franssen CFM, Hemmelder MH, ERACODA Collaborators. Clinical triaging of patients on kidney replacement therapy presenting with COVID-19: an ERACODA Registry analysis. *Nephrol Dial Transplant* 2021 Jun 15;gfab196. doi: 10.1093/ndt/gfab196. Online ahead of print.

294. Ottolina D, Zazzaron L, Trevisi L, Agarossi A, Colombo R, Fossali T, Passeri M, Borghi B, Ballone E, Rech R, Castelli A, Catena E, Nebuloni M, Gallieni M. Acute kidney injury (AKI) in patients with Covid-19 infection is associated with ventilatory management with elevated positive end-expiratory pressure (PEEP). *J Nephrol* 2021 Jun 25. doi: 10.1007/s40620-021-01100-3 Online ahead of print. Open access.

CAPITOLI DI LIBRI IN LINGUA INGLESE

1. Brancaccio D, Bugiani O, Pacini L, Bisceglia J, Padovese P, Gallieni M, Surian M, Costantini S, Giordano R, Baruffaldi M, Berlin A. Blood brain barrier derangement in aluminium intoxicated dialysis patients. In: A Taylor, ed. *Aluminium and other Trace Elements in Renal Disease*. London: Baillire Tindall - 1986; 19-23.

2. Brancaccio D, Ballerini L, Zoni U, Gallieni M, Magagnini G, Bestetti A, Cozzolino M, Sfondrini G, Tanieli R. Beta-2-microglobulin removal with CTA membranes. In: *Cellulose Triacetate*, Wichtig Editore, Milano 1994; 95-102.

3. Cozzolino M, Gallieni M, Galassi A, Brancaccio D. Calcium and Phosphate Physiology. In: C. Ronco, R. Bellomo, JA Kellum, eds. *Critical Care Nephrology*, Saunders Elsevier Health Sciences, 2nd edition. 2008;483-7

4. Gallieni M. Vascular access for chemotherapy. In: SE Wilson editor. *Essentials of Vascular Access*. A pocket reference. VASCUTEK, Inchinnan, Renfrewshire, UK. 1st edition. 2009; 104-16.

5. Gallieni M, Martini A, Olivi L. Catheter implantation and related complications. In: Tordoir J, Editor. *Best Practice in Vascular Access*. Edizioni Minerva Medica, Turin 2010; Chapter 6: 47-54.

6. Gallieni M, Mezzina N, Pinerolo C, Granata A. Sex/Gender Differences in Nephrology. In: Oertelt-Prigione S, Regitz-Zagrosek V, Editors. *Sex and Gender Aspects in Clinical Medicine*. Springer-Verlag London, UK, 2012; Chapter 7: 83-100.

7. Gallieni M. Characteristics of available peritoneal dialysis catheters. In: Davidson I, Gallieni M, Saxena R, Editors. Peritoneal Dialysis - Surgical Technique and Medical Management. DAVIDSON MEDICAL SERIES, Volume I. Divadi LLC, Dallas, Texas, USA 2012; Chapter 5: 91-109.
8. Cosmai L, Porta C, Ronco C, Gallieni M. Acute kidney injury in oncology and tumor lysis syndrome. In: Ronco C, Kellum JA, Bellomo R, Ricci Z, Editors. Critical Care Nephrology: Third Edition. Elsevier - Health Sciences Division, London, United Kingdom, 2019; Chapter 41: 234-250.
<https://doi.org/10.1016/B978-0-323-44942-7.00041-8> ISBN:9780323449427
9. Cosmai L, Sprangers B, Porta C, Gallieni M. Chronic Kidney Disease as a Complication of Cancer, With Special Focus on Kidney and Urothelial Tumors. In: Finkel K, Perazella M, Cohen E. ONCO-NEPHROLOGY. 1st Edition. Elsevier, Philadelphia, PA, USA, 2019; Chapter 33: 300-306.
eBook ISBN: 9780323549615; Hardcover ISBN: 9780323549455
10. Fusaro M, Plebani M, Tripepi G, Iervasi G, Cunningham J, Locatelli F, Zaninotto M, Aghi A, Mereu MC, Gallieni M. Vitamin K2 is a key regulator of clinically relevant molecular processes. In: Patel VB, Editor. Molecular Nutrition, Vitamins. Academic Press, Elsevier, London, United Kingdom, 2020; 153-172.
11. Granata A, Morale W, Ricciardi CA, Fiorini F, Forneris G, Gallieni M. Ultrasound-guided central venous catheter placement for hemodialysis. In: Granata A, Bertolotto M, Editors. Imaging in Nephrology. Springer Nature Switzerland AG 2021; Chapter 22; 269-279. Doi: 10.1007/978-3-030-60794-4_22

CAPITOLI DI LIBRO IN ITALIANO

1. Padovese P, Anelli A, Gallieni M, Brancaccio D. L'acetato di cellulosa come membrana alternativa per il trattamento dialitico ad alti flussi. In: "L'emodiafiltrazione ed i trattamenti ad alti flussi" a cura di Minetti L, Orlandini GC, Petrella E - Wichtig Editore, Milano. 1989; 357-359.
2. Gallieni M, Losi B, Padovese P, Cozzolino M, Carpani P, Brancaccio D. Iperparatiroidismo e anemia nell'insufficienza renale. In: Tecniche nefrologiche e dialitiche. Editoriale Bios, Cosenza. 1999: 281-289.
3. Gallieni M, Carpani P, Cozzolino M, Losi B, Brancaccio D. Prospettive future di terapia dell'anemia: le nuove molecole. In: Tecniche nefrologiche e dialitiche. Editoriale Bios, Cosenza. 1999: 291-302.
4. Gallieni M, Cozzolino M, Carpani P, Cainarca M, Tarricone C, Brancaccio D. La disinfezione nella dialisi. In: "La nefrologia tra linee guida e qualità" a cura di Maino V, Biasioli S, Tarchini R - J. Medical Books Edizioni, Viareggio (LU). 1999: 99-104
5. Gallieni M. Limiti e rischi del trattamento con idrossido di alluminio e/o supplementi di calcio. In: Tecniche nefrologiche e dialitiche. Editoriale Bios, Cosenza. 2002: 133-138.
6. Brancaccio D, Gallieni M. L'impiego di Sevelamer come chelante del fosforo alternativo. In: Tecniche nefrologiche e dialitiche. Editoriale Bios, Cosenza. 2002: 139-146.
7. Gallieni M, Cozzolino M, Galassi A, Chiarelli G, Brambilla C, Vezzosi G, Brancaccio D. I nuovi analoghi della vitamina D. In: Tecniche nefrologiche e dialitiche. Editoriale Bios, Cosenza. 2006: 3-12.

LIBRI

1. Garella S, Gallieni M. PROBLEM SOLVING. UN SYLLABUS DI FISOPATOLOGIA CON PROBLEMI CLINICI RELATIVI AI DISTURBI DEL METABOLISMO DEL SODIO, DEL POTASSIO E DELL'EQUILIBRIO ACIDO-BASE. Milano, Wichtig Editore 1989; 103 pagine.

2. Gallieni M, Slatopolsky E. DIALISI E OSTEODISTROFIA RENALE. PREVENZIONE E TRATTAMENTO DELLE ALTERAZIONI DEL METABOLISMO CALCIO-FOSFORO. Milano, Wichtig Editore 1991; 35 pagine, corredato di 24 diapositive.

3. Davidson I, Gallieni M, Saxena R, Editors. Peritoneal Dialysis - Surgical Technique and Medical Management. DAVIDSON MEDICAL SERIES, Volume I. Divadi LLC, Dallas, Texas, USA 2012; 198 pagine

TRADUZIONI DI LIBRI

1. Aronoff et al. PRESCRIZIONE DEI FARMACI NELL'INSUFFICIENZA RENALE. Indicazioni delle dosi negli adulti. Quarta Edizione. Torino, Centro Scientifico Editore 2000; 176 pagine

2. Levy J, Brown E, Daley C. MANUALE OXFORD DI DIALISI. Centro Scientifico Editore 2010; 775 pagine. ISBN:8876408568 EAN: 9788876408564

ORGANIZZAZIONE, DIREZIONE E COORDINAMENTO DI CENTRI O GRUPPI DI RICERCA NAZIONALI E INTERNAZIONALI O PARTECIPAZIONE AGLI STESSI

Gruppi o società scientifiche nazionali

1989-1991 Coordinatore, Italian Group for the Study of Intravenous Calcitriol

2007-2008. Coordinatore, Gruppo di Studio Accessi Vascolari, Società Italiana di Nefrologia

2012-2016 Componente del Gruppo di ricerca nazionale "REport of COmorbidities in non-dialysis Renal Disease population in ITaly (RECORD-IT)", Società Italiana di Nefrologia

2013 - presente. Coordinatore della Commissione interdisciplinare di onconeurologia SIN-AIOM, Società Italiana di Nefrologia, Associazione Italiana di Oncologia Medica

2016-2018. Membro del Consiglio di Indirizzo Scientifico, Centro di Ricerca Coordinata di Immunopatologia Renale dell'Università degli Studi di Milano. Dipartimento di Scienze Biomediche e Cliniche (DIBIC) "L. Sacco".

2017-2019 Italian Chapter, Vascular Access Society. Fondatore e coordinatore.

2019 - presente. Clinical PI, PRINTMED-3D, piattaforma integrata per tecnologie mediche tridimensionali. <https://printmed-3d.com/progetto/>

Gruppi o Società scientifiche internazionali

Vascular Access Society, Maastricht, Netherlands

2009-2011: Board member; 2011-2013: President Elect; 2013-2015: President; 2015-2017: Past-president; 2017-2021: Council member

2013-2016 Partecipante al progetto internazionale di raccolta dati International Society of Nephrology's Kidney Disease Data Center (ISN-KDDC) su malattia renale cronica e rischio cardiovascolare, finanziato da grant Program for Detection and Management of Chronic Kidney Disease, Hypertension, Diabetes, and Cardiovascular Disease in Developing Countries (KHDC) of the Global Outreach (GO), Research and Prevention Committee, International Society of Nephrology (ISN).

2014. European Gender Medicine Network - EUGenMed: Sex and gender in clinical medicine and clinical pharmacology. Partecipazione al Progetto.

2015-2018. Partecipante al gruppo di sviluppo delle linee guida sull'accesso vascolare per dialisi, European Society of Vascular Surgery (ESVS)

2016-2019. Coordinatore gruppo di sviluppo delle linee guida sull'accesso vascolare in dialisi, European Renal Association - European Dialysis and Transplant Association (ERA-EDTA)

2017. Partecipante al gruppo di lavoro Standardized Outcomes in Nephrology-Hemodialysis (SONG-HD) per la definizione di "Core Outcome Measure for Hemodialysis Vascular Access".

2018-2020 Coordinatore del "SAVE Registry" (Surfacer® Inside-Out® Access Catheter System in Patients with Thoracic Venous Obstruction)

2018 - presente. Expert panel coordinator. AVATAR (Association of Vascular Access and intervenTionAl Renal physicians, www.AVATAR.net.in). Workgroup of 15 national nephrology societies of South and Southeast Asia countries (India, Pakistan, Brunei, Bangladesh, Sri Lanka, Nepal, Myanmar, Thailand, Singapore, Malaysia, Vietnam, Taiwan, Philippines, Indonesia and Hong Kong).

2021. Gruppo di lavoro "Assisted PD Think Tank" sullo sviluppo della dialisi peritoneale assistita

ATTIVITÀ QUALI LA DIREZIONE O LA PARTECIPAZIONE A COMITATI EDITORIALI DI RIVISTE SCIENTIFICHE

Dal 2009: Editor in Chief, Journal of Vascular Access - <https://journals.sagepub.com/editorial-board/JVA>

Altri incarichi attivi:

Associate Editor, BMC Nephrology

Associate Editor, Scientific Reports Nature

Membro dell'Editorial Board dei seguenti giornali scientifici

- Journal of Nephrology
- Giornale Italiano di Nefrologia
- Journal of OncoNephrology

PREMI E RICONOSCIMENTI NAZIONALI E INTERNAZIONALI PER ATTIVITÀ DI RICERCA

2007. Premio International Society of Nephrology (ISN) Renal Pathology and Research and Prevention Grants per il Progetto "Early Detection Program for Chronic Kidney Disease, Hypertension, Diabetes and Cardiovascular Diseases in Kolkata, West Bengali, India: A study to design and establish intervention programs"

2007. Premio CEC - Clinical Evidence Council, Baxter USA, per uno studio di ricerca sui pazienti in dialisi peritoneale, svolto in collaborazione con la University of British Columbia, Vancouver, Canada.
2010. Responsabile di Unità locale del progetto di Ricerca Finalizzata "SALUTE-CKD (SALT lowering by Urine sodium self-measurement Trial in Chronic Kidney Disease)" - Codice progetto: RF-2010-2314890, Principal investigator: Carmine Zoccali.

2016. Keynote lecture, American Society of Diagnostic & Interventional Nephrology (ASDIN) - 12th Annual Scientific Meeting - Phoenix, Arizona, USA, 20 febbraio 2016. Gerald Beathard Annual State of the Art Lecture. "Innovations in Vascular Access - Have We Moved Forward?"

2020. Vincitore progetto Erasmus+, European Union. "N-PATH Nephrology Partnership for Advancing Technology in Healthcare". Capofila Progetto: Università di Bari.

2021. Honorary Membership, the Vascular Access Society, April 2021

PARTECIPAZIONE IN QUALITÀ DI RELATORE A CONGRESSI E CONVEGNI DI INTERESSE INTERNAZIONALE

Si forniscono dati sulle presentazioni a congressi internazionali degli ultimi tre anni.

2019

EVC (European Vascular Course). Maastricht, the Netherlands. Presentazione "Interventions for PD catheter complications"

International Vascular Access Symposium. Paris, France. Presentazione "Alternative means for hemodialysis access"

CIDA (Controversies in Dialysis Access). San Diego, CA, USA. Presentazione "Wearable Peritoneal Dialysis"

ASN (American Society of Nephrology). Washington, DC, USA. Presentazione "High Cut-Off Dialysis for Cast Nephropathy: Does It Really Help?"

JSDA (Japanese Society for Dialysis Access). Yokohama, Japan. Presentazione "Vascular access and renal transplantation"

2020

ASDIN (American Society of Diagnostic and Interventional Nephrology). Las Vegas, USA. Presentazione "Managing the Complications of Peritoneal Dialysis"

VASA (Vascular Access Society of the Americas). Online. Presentazione "The Global Dialysis Access Forum (GDAF) Session: Global unification with scientific publication"

ERA-EDTA. Online. **How to choose the right dialysis access for an individual patient**

2021.

ASDIN (American Society of Diagnostic and Interventional Nephrology). Online. Presentazione "Impact of COVID-19 on dialysis access"

VAS (Vascular Access Society). Online. Presentazioni. Current state of vascular access; Simulation training.

WoCoVA (World Congress Vascular Access). Online. Presentazione “Dialysis Central venous catheters” ERA-EDTA. Online. 1. Organizzatore e relatore di workshop su accessi vascolari. 2. Presentazione sul progetto Europeo N-PATH

ATTIVITÀ GESTIONALI, ORGANIZZATIVE E DI SERVIZIO

INCARICHI DI GESTIONE E AD IMPEGNI ASSUNTI IN ORGANI COLLEGIALI E COMMISSIONI, PRESSO RILEVANTI ENTI PUBBLICI E PRIVATI E ORGANIZZAZIONI SCIENTIFICHE E CULTURALI, OVVERO PRESSO L'ATENEIO O ALTRI ATENEI

2015-2018. Coordinatore linee guida accesso vascolare. ERA-EDTA

2018 - presente. Vice-Presidente del Collegio Didattico, Corso di Laurea magistrale a ciclo unico LM-41 - Medicina e chirurgia, polo Vialba

2019 - presente. Presidente Commissione TERZA MISSIONE, Dipartimento di Scienze biomediche e cliniche 'Luigi Sacco', Università degli Studi di Milano

2012 - presente. Componente del consiglio di amministrazione dell'organizzazione di volontariato Project for People, Milano

ETICA IN MEDICINA:

2011 - 2013: Componente del Comitato Etico, Ospedale San Carlo Borromeo, Milano

2013 - presente: Consulente nefrologo per il Comitato Etico interaziendale, Ospedale Sacco, Milano

ATTIVITÀ CLINICO ASSISTENZIALI

Ospedale San Paolo, Milano, Polo Universitario (1989-2009)

1989-1993: Assistente Nefrologo di ruolo presso il Servizio Dialisi, Ospedale San Paolo di Milano

1994-2004: Aiuto Nefrologo - presso lo stesso reparto

2002-2009: Direttore della U.O. semplice di tipo B “Insufficienza renale”, Ospedale San Paolo di Milano.

2002-2009: Responsabile del programma Dialisi Peritoneale.

2004-2009: Vicedirettore U.O. complessa di Nefrologia e Dialisi

Azienda Ospedaliera San Carlo Borromeo, Milano (1/11/ 2009 - 31/12/ 2015)

Direttore U.O. Complessa di Nefrologia e Dialisi

ASST Santi Paolo e Carlo (1/1/2016 - 30/11/2018)

Direttore U.O. Complessa di Nefrologia e Dialisi, Polo Ospedaliero San Carlo

ASST Fatebenefratelli Sacco (dal 1/12/2018 ad oggi)

Direttore U.O. Complessa di Nefrologia e Dialisi, Presidio ospedaliero Sacco e Presidio ospedaliero Fatebenefratelli

Data

26 giugno 2021

Luogo

Milano